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Common obesity is a multifactorial trait, where an “obesogenic” environment of caloric 
abundance and ubiquitous automation, sedentary lifestyle, and genetic susceptibility 
interact to result in the obesity.   
Aim 
To investigate the role of three candidate genes in the pathogenesis of childhood obesity: 
1. Pro-opiomelanocortin gene (POMC) 
2. Melanocortin-4 receptor gene (MC4R) 
3. melanocortin-3 receptor gene (MC3R) 
Methods 
More than 200 severely obese local children (Singapore) with percentage weight for 
height >150% were recruited to our Obesity Gene Study (OGS).  MC3R and MC4R genes 
of this cohort were screened by direct sequencing.  The POMC gene of more than 900 
DNA samples from the Genetics of Obesity Study (GOOS) (Cambridge, UK) were 
screened using a combination of direct sequencing and denaturing high performance 
liquid chromatography (dHPLC).   
Results 
From 201 study subjects (OGS), three novel heterozygous MC3R mutations (Ile183Asn, 
Ala70Thr, and Met134Ile) were identified in three unrelated subjects.  Compared to obese 
controls, the heterozygotes demonstrated higher leptin levels and adiposity, and less 
hunger.  Family studies showed these mutations may be associated with childhood obesity.  
Two common variants Thr6Lys and Val81Ile in complete linkage disequilibrium were also 
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found.  Obese subjects with the 6Lys/81Ile haplotype had significantly higher leptin levels, 
percentage body fat, and insulin sensitivity.  The mutant and 6Lys/81Ile receptors 
demonstrated impaired signaling in-vitro.   
 
Three MC4R mutations were identified in three subjects from 227 local obese children 
(OGS): c.631-634delCTCT, Tyr157Ser, and c.976delT. Signaling activities of the 
Tyr157Ser and c.976delT mutant receptors were impaired in-vitro.  
 
In 538 Caucasian subjects with severe, early-onset obesity (GOOS), five probands were 
heterozygous for a rare missense variant in the region encoding β-MSH, Tyr221Cys. This 
frequency was significantly increased compared to the general UK Caucasian population, 
and the variant co-segregated with the obesity/overweight phenotype in affected family 
members. Obese children carrying the Tyr221Cys variant of β-MSH were hyperphagic 
and showed increased linear growth, reminiscent of MC4R deficiency. We also found a 
heterozygous POMC mutation His143Gln in one obese subject, which affected the core 
binding motif of α-MSH. However, the transmitting parent was not obese. Both mutant 
peptides demonstrated impaired binding and activation of the MC4R in-vitro. The results 
supported the role of β-MSH in human energy homeostasis.  Compared to α-MSH, β-
MSH may even be the more critical mediator of melanocortin signaling pathway in 
humans.  
 
POMC screening of the GOOS cohort also revealed two heterozygous missense 
mutations, Cys28Phe and Leu37Phe, which resulted in substitution of highly conserved 
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residues of the sorting signal motif of POMC. Cys28Phe and Leu37Phe co-segregated 
with obesity/overweight in the families.  In-vitro studies revealed less efficient sorting 
and processing of the two mutant POMC peptides, with less α-MSH production. 
Conclusion 
MC4R mutations resulted in an autosomal codominant form of obesity with variable 
expressivity. Heterozygous MC3R and POMC mutations did not result in autosomal 
dominant forms of obesity, but may contribute as predisposing factors to early-onset 
obesity, and exert an effect on the human phenotype.  
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Genetics of Obesity and the Weight Regulation Mechanism 
 
Obesity as a multifactorial trait 
Obesity is a global pandemic and a major health concern because of associated 
morbidities such as type 2 diabetes, hypertension, and coronary heart disease, and 
consequent premature mortality.  The increasing obesity prevalence all over the world 
has been attributed to industrialisation and modernization which created an “obesogenic” 
environment that encourages sedentary lifestyle and increased calorie intake (Bell et al., 
2005; French et al., 2001). This results in imbalance of energy intake and expenditure, 
and the net deposition of calories as fat. Although this trend of increasing body girth is 
very much driven by the “obesogenic” environment, it is facilitated by the individual’s 
genetic susceptibility to excessive weight gain (Bouchard, 1991).   
 
Obesity is a common but highly complex, multifactorial disorder of polygenic 
inheritance, which evolved from interaction between the modern “obesogenic” 
environment and the individual’s genetic susceptibility to excessive weight gain.  While 
it is well established that obesity runs in families, the familial clustering is not just due to 
a common lifestyle and shared environment.  Studies in twins, adoptees, and families 
indicate that as much as 80 percent of the variance in the body mass index (BMI) is 
attributable to genetic factors. Relative risk of obesity among sibs was estimated to be 3 
to 7 (Allison et al., 1996a), the concordance rate of obesity is higher between 
monozygotic twins than dizygotic twins (Allison et al., 1996b; Maes et al., 1997; 
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Stunkard et al., 1986a), and adoptees’ weight is often closer to their biological parents 
than their adoptive parents (Stunkard et al., 1986b). These and several other 
comprehensive studies incorporating twins, adoptees and family data have estimated the 
heritability of BMI or body fat to be  25-40% (Bouchard et al., 1988; Stunkard et al., 
1986b; Tambs et al., 1992; Vogler et al., 1995) 
 
These studies, as well as numerous linkage and association studies, supported the 
role of genes in the pathogenesis of human obesity.  However, obesity has a wide 
phenotypic variability, ranging from the mildly overweight to the morbidly obese, as well 
as the spectrum of early (childhood) to late (adult) onset.  The relative contribution of the 
environment and genetic susceptibility towards the pathogenesis of obesity varied 
between different obese individuals, even within the same family, and may contribute to 
this phenotypic variability. The environment and a sedentary lifestyle may be the 
dominant contributing factor in the development of late onset obesity in an adult, while 
genetic factors may exert a greater influence in a young child who developed early onset 
obesity in the ‘obesogenic’ environment, and such notion is supported by the knowledge 
that the heritability of early-onset obesity may be considerably higher than that of adult-
onset obesity (Stunkard et al., 1986b). This heterogeneity may even extend to the 
individual’s response to weight-losing measures. Individuals where environmental factors 




While family, twins and adoption studies as well as numerous linkage and 
association studies have provided considerable evidence which supported the genetic 
basis for human obesity, the current rapidly increasing prevalence of obesity is a 
relatively recent global event which occurred only in the last few decades.  It is 
inconceivable that genetic mutations or major shifts in allelic frequencies of obesity-
related genes are responsible for this, given the stable gene pool of the world’s population 
in this short period of time (Flegal et al., 2002; Leibel, 2006). However, though the role 
of the obesity genes in this current epidemic is likely passive, its impact is highly 
significant, because individuals with these genes may be predisposed to severe or even 
morbid obesity when exposed to the modern “obesogenic” environment. Historically, 
mankind has faced prolonged periods of starvation and hardship, and was constantly 
required to gather or hunt for food. The ability to conserve energy in the form of adipose 
tissue would therefore confer a significant survival advantage, where the human body is 
enriched with genes which favour the storage of energy, and diminished energy 
expenditure (thrifty gene hypothesis), and therefore more likely to survive natural 
selection over the past centuries (Bell et al., 2005; Neel, 1962).  
 
The human weight regulatory mechanism thus evolved, becoming more efficient 
in preventing weight loss, but relatively ineffective in preventing excessive weight gain.  
The modern “obesogenic” environment of industrialized countries developed over the 
past few decades in our bid to reduce work and improve efficiency and quality of life.  
The workforce became increasingly sedentary and reliant on machines and automation.  
Coupled with easy access to processed food, this led to reduction of energy expenditure 
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and increased caloric intake. While human ingenuity has succeeded in creating an 
environment of work efficiency and plenty, it has also inadvertently created a biology-
environment mismatch, as the human weight regulation is unable to evolve fast enough to 
keep pace with the environmental change.  This resulted in maladaptation of an otherwise 
sound and metabolically efficient physiological mechanism, with serious metabolic 
consequences. Consequently, the proportion of overweight people has risen steadily over 
the years.  In particular, there is a pronounced increase in morbid obesity which cannot be 
explained by a mere shift in population mean (Flegal et al., 2002). The hypothesis is that 
the “obesogenic” environment has caused a subgroup of the population, who are 
genetically susceptible to severe weight gain, to become excessively obese (Friedman, 
2003).  These individuals may possess the ‘thrifty genes’ (obesity genes) which would 
otherwise be protective against starvation (and therefore confer selection advantage 
historically), but in the present day ‘obesogenic’ environment might develop severe 
obesity, such as high risk groups like the Pima Indians, Pacific Islanders, Afro-Americans 
and Hispanic-Americans (Cossrow and Falkner, 2004).  
 
Obesity gene research has advanced rapidly over the past two decades, which 
provided revelation of the molecular mechanism of energy homeostasis in the process.  
Traditional methods employed to uncover these obesity genes include genome-wide 
scans which studied unrelated obese individuals, linkage studies which examined related 
pairs or families with obesity, and association studies which investigated association 
between obesity and polymorphic variants of candidate genes predicted to affect weight 
regulation. Unlike other multifactorial disorders, these approaches have not been as 
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promising for common obesity, because the obese phenotype is very heterogeneous, even 
within the same family. There is variable contribution from genetic, environmental and 
behavioural influences which differ for every obese individual, which confounded efforts 
to analyse this condition. While several syndromic forms of human obesity such as 
Prader-Willi syndrome and Bardet-Biedl syndrome have been genetically mapped and 
causative genes identified, their exact roles in the pathogenesis of obesity and the 
underlying molecular mechanisms have not been isolated yet (Boutin and Froguel, 2001). 
 
Monogenic obesity illuminates the molecular circuitry of energy homeostasis  
While the search for obesity genes has posed a major challenge, we have witnessed 
significant milestones in obesity gene research in the last decade, in the discovery of 
novel single gene defects which result in human obesity, namely leptin deficiency, leptin 
receptor deficiency, proopiomelanocortin (POMC) deficiency, prohormone convertase 1 
deficiency (PC1), melanocortin 4 receptor deficiency, and tyrosine kinase B (TrkB) 
deficiency.  These monogenic forms of human obesity resulted in deficiency of critical 
molecules and disruption of the leptin-melanocortin system which lead to the obese 
phenotype, and thus provide validation of the role of the leptin-melanocortin system in 
energy homeostasis, and unravel the molecular circuitry of human weight regulation. 
    
Human energy homeostasis is regulated by a complex physiological system that 
requires the integration of several peripheral signals and central coordination in the brain 
to maintain a balance between food intake and energy expenditure. The hypothalamus 
functions as the central regulator in this system, in particular the arcuate nucleus which 
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has an essential role. The monogenic forms of human obesity as well as studies of 
knockout mouse models validate the critical mediators of this weight regulation loop, by 
demonstrating that deficiencies of these molecules result in obesity unequivocally and 
also endorse the crucial role of the leptin-melanocortin pathway. 
 
The Leptin-Melanocortin System 
Various human and murine genetic studies have shed light on the biological weight 
regulation mechanism, akin to pieces of a jigsaw puzzle being put together which 
progressively unravel this integral system.  Excess food intake is stored in adipose tissue. 
Adipose tissue secretes leptin in response to increased fat storage, which circulates as an 
afferent satiety signal and activates hypothalamic neurons expressing pro-
opiomelanocortin (POMC) located in the arcuate nucleus, which innervates other 
hypothalamic regions known to regulate feeding behaviour (Cowley et al., 2001; Heisler 
et al., 2002; Saper et al., 2002). Pro-opiomelanocortin (POMC) is a polypeptide that 
undergoes tissue-specific post-translational processing, the products of which include the 
melanocortin peptides α, β, and γ-melanocyte-stimulating hormones (MSH) (Raffin-
Sanson et al., 2003).  One or more of the three melanocortin peptides is/are involved in 
the anorectic response by stimulating melanocortin-4 receptors (MC4R) on neurons 
downstream in the paraventricular nucleus (PVN) (Farooqi et al., 2003; Farooqi et al., 
2000; Huszar et al., 1997; Schwartz et al., 2000; Vaisse et al., 2000), and melanocortin-3 
receptors (MC3R) to reduce feed efficiency, which is the ability to convert food to fat 
stores (Butler et al., 2000; Chen et al., 2000; Feng et al., 2005; Lee et al., 2007b; Lee et 
al., 2002). The melanocortin system thus mediates the anorexigenic effects of leptin, 
  7
reducing food intake and increasing energy expenditure.  MC3R is also located on POMC 
expressing neurons in the arcuate nucleus, and may form part of a feedback loop which 
negatively regulates the anorexic tone of the POMC expressing neurons (Jegou et al., 
2000), where melanocortin peptides from activated POMC neurons negatively 
autoregulate further POMC expression through their inhibitory actions at the MC3R.  
Recent evidence suggests that the tyrosine kinase B receptor and the brain derived 
neurotrophic factor (Xu et al., 2003; Yeo et al., 2004) and nesfatin (Oh et al., 2006) are 
critical mediators downstream of MC4R. Leptin also inhibits neurons co-expressing the 
orexigenic neuropeptide Y and agouti-related peptide in the arcuate nucleus, which will 
otherwise promote feeding activity (Gropp et al., 2005). A schematic of this intricate 
leptin-melanocortin weight regulation system is illustrated in figure 1-1. 
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Figure 1-1. The leptin-melanocortin system. Leptin secreted by adipose tissue as satiety 
signal crosses the blood brain barrier to stimulate the melanocortin neurons in the arcuate 
nucleus of the hypothalamus, and upregulate production of POMC, which is broken down 
to neurotransmitter α-MSH and in turn stimulate MC4R and MC3R of neurons 
downstream to reduce food intake, increase metabolic rate, and decrease feed efficiency 
(i.e. stimulation of the anorexigenic pathway). Leptin also concomitantly inhibits the 
orexigenic pathway by exerting inhibition on the AGRP/NPY neurons in the arcuate 
nucleus. 
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The Elusive Satiety Factor 
The regulation of energy balance has been the focus of discussion dating back to 1783, 
and the quest to understand the weight regulation mechanism started with the search for 
the satiety factor.  The body’s energy balance was postulated then to be controlled by a 
feedback loop, in which the amount of stored energy is sensed by the hypothalamus, 
which adjusts the food intake and energy expenditure to maintain a constant body weight.  
It is now established that the paraventricular nucleus (PVN), ventromedial nucleus 
(VMN), dorsomedial nucleus (DMN), and arcuate nuclei (ARC) are the satiety control 
centers of the hypothalamus (Choi and Dallman, 1999; Cowley et al., 2001). Studies on 
rat models have shown that disruption of ARC, PVN and VMN produced increased food 
intake and obesity, and disruption of DMN produced decreased food intake. 
 
The classical parabiotic (cross circulation) experiments by Hervey and other 
investigators demonstrated that there was a circulating satiety factor in the blood stream 
which regulates food intake (Coleman, 1973; Harris and Martin, 1984; Hervey, 1969): 
 
a) overfeeding one of a pair of parabiotic mice (which were surgically joined with 
interchange of blood) reduced food intake and induced weight loss in the partner, 
apparently because of the transfer of a circulating hormone. 
 
b) when an ob/ob mouse (obese mouse due to genetic defect and lacking the circulating 
satiety factor) was surgically joined to a normal animal, it ate less and gained less 
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weight.  This occurred because the ob/ob phenotype which resulted from lack of the 
proposed satiety hormone was supplied by the normal animal in the parabiotic pair.   
 
c) Mice homozygous for the db mutation were also obese.  This db/db phenotype was 
due to a deficiency of the hypothalamic receptor for the purported satiety factor.  
When a normal mouse is paired with a db/db mouse, it rejected food and died of 
starvation, presumably due to an excess of the satiety factor from the db/db mouse. 
 
Leptin 
It is now established that the primary product of the ob gene is the satiety factor termed 
leptin, and the mice with the ob mutation (now designated Lepob) have a deficiency of 
leptin (due to a premature stop codon resulting in a truncated protein), while the mice 
with the db mutation (now designated Leprdb) are deficient in the hypothalamic receptor 
for leptin (Leibel et al., 1997; Tartaglia et al., 1995; Zhang et al., 1994).   
 
The discovery of leptin (Zhang et al., 1994) and the leptin receptor (Tartaglia et 
al., 1995) heralded a new era in obesity research. The protein, “leptin”, is derived from 
the Greek word ‘leptos’, meaning thin.  The etymology of the word “leptin” implies that 
its physiological role is primarily to suppress body fat, by decreasing food intake and 
increasing energy expenditure.  Leptin is a 167 amino acid peptide made exclusively in 
adipose tissue in a wide range of animal species, including humans.  The ob gene is 
located on the mouse chromosome 6, and the human homologue of the ob gene has been 
mapped to chromosome 7q31.3 (Friedman et al., 1991; Geffroy et al., 1995). Northern 
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blot or RT-PCR analysis of the messenger ribonucleic acid (mRNA) for the ob gene 
showed that it was expressed only in adipose tissue (Zhang et al., 1994).   
 
Leptin is secreted by adipocytes as an afferent satiety signal, produced in 
proportion to the mass of adipose tissue, which acts as an endocrine organ.  Both human 
and animal studies have demonstrated the close association between body fat, leptin 
mRNA, and the plasma leptin levels (Halaas et al., 1995; Levin et al., 1996; Weigle et al., 
1995). Increase in fat storage will lead to increased leptin, which inhibits the satiety 
center in the hypothalamus, and also influences other neuroendocrine systems, including 
those related to puberty and fertility.  There appears to be a lipostatic set point for weight 
regulation, in which the body will maintain a certain weight and body composition.  
 
 Leptin also has peripheral effects other than its central role in weight regulation. It 
stimulates oxidation of fatty acids in mitochondria and uptake of glucose in muscles, and 
prevents damaging accumulation of lipids in non-adipose tissues (lipotoxicity).  Leptin 
stimulates 5’-AMP-activated protein kinase (AMPK) which increases fatty acid 
consumption and oxidation, and reduces fat storage.  This reduces fat accumulation in 
muscle and liver cells, which in turn reduces insulin resistance (Friedman, 2002; 
Minokoshi et al., 2002). 
 
In the ob/ob (leptin deficient) mice, systemic or intra-cerebroventricular 
administration of leptin reduces food intake and increases energy expenditure, resulting 
in reduced body fat.  It also increases activity of the sympathetic nervous system, 
  12
decreases insulin, reduces glucose and improves insulin-sensitive glucose disposal 
(Campfield et al., 1995; Halaas et al., 1995; Pelleymounter et al., 1995; Schwartz et al., 
1996a).  Supraphysiological doses of leptin have similar effects in non-obese animals 
(Collins et al., 1996). In order to promote weight loss in normal lean mice or obese adults, 
leptin must be administered in doses that raise serum leptin concentrations by 20 to 30 
times the normal level for a given fat mass (Campfield et al., 1995; Heymsfield et al., 
1999). It is therefore proposed that the principal function of leptin is to maintain the body 
fat mass, and the system may be more adept at preventing weight loss than weight gain, 
by signaling to the brain that calorie intake and the amount of energy stored as fat are 
sufficient (Rosenbaum and Leibel, 1999). In such a model, the depletion of fat mass 
during starvation leads to reduced leptin synthesis per fat cell.  The reduced action of 
leptin on the hypothalamus initiates compensatory changes in energy intake and output, 
which favours a return to the usual body weight.  The threshold concentration of leptin 
below which these changes occur, is highly individualized, and influenced by genetic and 
developmental factors.  Any further elevation of serum leptin concentration above the 
threshold will have little effect on energy homeostasis, except for supraphysiological 
levels such as leptin administration. 
 
The majority (>90%) of people with common obesity were hyperleptinemic, and 
do not have low leptin levels or mutations of the leptin gene (Considine et al., 1995; 
Maffei et al., 1996). On the contrary, there is strong positive correlation between serum 
leptin concentrations and the percentage body fat, body mass index, and basal insulin 
concentrations (Considine et al., 1996b; Maffei et al., 1995), and leptin levels are reduced 
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in obese individuals who lose weight (Halaas et al., 1995). This led to the hypothesis of 
resistance to the action of leptin in these individuals, so that the increase in adipose tissue 
mass is maintained.  As the vast majority of obese individuals do not have defective 
leptin receptors and therefore not contributory to the hyperleptinemia observed 
(Considine et al., 1996a; Gotoda et al., 1997), the relative insensitivity of the 
hypothalamic satiety centre to leptin action may be due to abnormal carriage of leptin 
across the blood brain barrier (Caro et al., 1996; Schwartz et al., 1996b), or more 
intriguingly, defective mediators in the pathway distal to the leptin receptor. This 
hypothesis is obviously shared by many, given the myriad of research in quest of genetic 




Leptin deficiency from disruption of both leptin genes result in severe obesity in mice 
and humans.  The ob/ob (leptin deficient) mouse is characterized by obesity, hyperphagia, 
hyperglycemia (Schwartz et al., 1996a), hyperinsulinemia due to insulin resistance (Bray 
and York, 1971), hypothermia (Trayhurn et al., 1977), impaired hypothalamic-pituitary-
thyroid axis (Ohtake et al., 1977), and hypogonadotropic hypogonadism causing 
infertility (Swerdloff et al., 1976), and leptin replacement reverses these endocrine and 
metabolic defects (Campfield et al., 1995; Halaas et al., 1995; Pelleymounter et al., 1995).   
 
Human congenital leptin deficiency is rare.  Five children from three 
consanguineous Pakistani families were reported to be homozygous for a frameshift Lep 
mutation comprising of a single G deletion affecting codon 133 (∆133G), which led to 14 
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aberrant amino acids, followed by a premature stop codon (Farooqi et al., 2002; Farooqi 
and O'Rahilly, 2004; Gibson et al., 2004; Montague et al., 1997).  The mutant leptin was 
not secreted, but accumulated intracellularly as a consequence of misfolding and 
aggregation, and was subsequently degraded by the proteasome (Rau et al., 1999). There 
were also three related Turkish subjects homozygous for a missense mutation Arg105Trp 
due to a C to G transition, which resulted in impaired processing and secretion of leptin 
(Strobel et al., 1998). 
   
These individuals had undetectable or very low leptin levels, and exhibit extreme 
early onset obesity.  Their birth weights were within normal limits, but rapidly become 
obese by 3 to 4 months of age, with marked hyperphagia and were constantly hungry.  
They had high percentage body fat of 54 to 57%, and linear growth was not stunted with 
IGF-I levels within normal range.  Bone age was advanced by about 2 years, but bone 
mineral density (BMD) was appropriate for age and gender.  There was no evidence of 
impairment in basal or total energy expenditure, and body temperature was normal, 
unlike the ob/ob mice, whose oxygen consumption, energy expenditure, and body 
temperature were low (Montague et al., 1997). Thus, leptin may be less central to the 
regulation of energy expenditure in humans than in mice. Another difference in humans 
with either leptin or leptin receptor mutations was the consistently normal glucocorticoid 
concentrations, in contrast to the marked excess in ob/ob mice.  The human cases with 
leptin deficiency had hypogonadotropic hypogonadism, with delayed puberty or primary 
amenorrhoea, yet had normal responses to short human chorionic gonadotropin 
stimulation test (test of gonadal function) and gonadotropin releasing hormone 
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stimulation test (test of pituitary function), which were suggestive of a hypothalamic 
defect.  
 
Three leptin deficiency children homozygous for the ∆133G mutation received up 
to 50 months of recombinant human methionyl leptin (R-metHuLeptin) replacement, 
administered as subcutaneous injections once daily, in escalating doses if weight gain 
was documented over two successive 2 month periods, to achieve 10, 20, 50, 100 and 
150% of predicted leptin concentration based on height and weight (Farooqi et al., 2002). 
There was dramatic weight loss which started within 2 weeks of initiation, and sustained 
through the trial period.  Refractory periods of weight gain did occur but were overcome 
with increases in leptin doses.  Fat mass represented 98% of the weight loss, with 
reciprocal increase in lean mass, and there was reduced food intake up to 84% during ad 
libitum meal tests.  It was so successful that a morbidly obese boy weighing 42 kg at 3 
years of age achieved normal weight after 2 years of therapy, weighing 32 kg (75th 
percentile on local weight chart) after 48 months of treatment.  There was no discernible 
change in basal and total energy expenditure.  An 11-year-old prepubertal girl with 
congenital leptin deficiency who received leptin replacement began to manifest pubertal 
progress subsequently, with gradual increase in pulsatility of gonadotropins, and achieved 
regular menstrual cycles by 12.1 years.  The other 2 younger children (<6 years) 
remained appropriately prepubertal during leptin replacement.  Congenital leptin 
deficiency caused hypogonadism and pubertal failure, but leptin replacement permitted 
puberty to progress appropriately in the 11 year old girl but yet did not cause precocious 
puberty in the other two younger children.  The authors proposed that leptin may act as a 
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permissive metabolic gate which allowed progression of appropriately timed pubertal 
development. These reports of human leptin deficiency and the effects of leptin 
replacement provided the first evidence of the importance of leptin in energy regulation 
as well as endocrine functions in humans.  
 
Family studies showed that leptin deficiency was inherited in an autosomal 
recessive fashion.  However, though heterozygotes for the mutant Lep gene were not 
morbidly obese, 76% of them were obese with BMI more than 30 kg/m2. The blood 
leptin levels of these heterozygotes were lower than matched controls, with poor 
correlation between body fat mass and leptin levels, and their body fat percentage 
exceeded the predicted body fat percentage(Farooqi et al., 2001). This observation 
demonstrated that haploinsufficiency of one Lep gene may result in increased adiposity, 
lower leptin, and higher likelihood of obesity, but not to the extent of an intermediate 
phenotype typical of an autosomal co-dominant condition. The study of this group of 
individuals who are partially deficient in leptin also showed that differences in circulating 
leptin levels, within the range found in normal humans, can directly influence adiposity. 
 
Leptin Receptor Deficiency 
The leptin receptor is a member of the cytokine family of receptors with several splice 
variants.  The long leptin receptor isoform is considered the principal signaling isoform.  
The intracellular signaling system for leptin appears to involve activation of the JAK-
STAT system, with Stat-3 being the phosphorylated intermediate. The human LEPR gene 
has been mapped to chromosome 1p31.  Leptin receptors are distributed widely, 
  17
including brain and many peripheral tissues (lungs, kidneys, muscle, and adipose tissue), 
suggesting that this peptide may provide a wide range of tissues with information about 
fat stores.  If obesity in humans were due to leptin receptor mutations, then one would 
expect a much higher leptin concentration than predicted, based on fat mass, but this is 
not the case (Rosenbaum et al., 1996). Considine et al examined expression of the LEPR 
gene in the hypothalamic tissue from 7 lean and 8 obese humans obtained shortly after 
autopsy (Considine et al., 1996a). Using RT-PCR, there was no difference in the amount 
of LEPR mRNA between the lean and obese subjects.  A Gln23Arg polymorphism due to 
A-to-G substitution at nucleotide 668 of the LEPR cDNA was detected, where 11 
subjects were heterozygous and 3 were homozygous. The occurrence of the polymorphic 
allele(s) did not correlate with the body mass index in the patients studied.  The results 
suggested that leptin resistance observed in obese humans is unlikely to be due to a defect 
in the leptin receptor. Gotoda et al determined the entire coding sequence of the human 
leptin receptor cDNA from peripheral blood lymphocytes of 22 morbidly obese patients 
(Gotoda et al., 1997). Five common DNA sequence variants were found to be distributed 
throughout the coding sequence at codons 109, 223, 343, 656, and 1019, with one rare 
silent mutation at codon 986, as well as a novel alternatively spliced form of transcript.  
None of the five common variants, including three that predict amino acid changes, were 
null mutations causing morbid obesity, because homozygotes for the variant sequences 
were also found in lean subjects. Furthermore, the frequency of each variant allele and 
the distribution of genotypes and haplotypes were similar in 190 obese and 132 lean 
white British males selected from a population-based epidemiologic survey. The results 
  18
suggested that these are polymorphisms, and that mutations in the leptin receptor gene are 
not a common cause of human obesity. 
 
 The diabetes (db/db) mouse had abnormal splicing of the long (hypothalamic) 
leptin receptors(Lee et al., 1996), and had features similar to that of the ob/ob (leptin 
deficient) mouse. There was early onset morbid obesity with hyperphagia and reduced 
energy expenditure, infertility secondary to hypogonadotropic hypogonadism, diabetes 
with dyslipidemia, hypercortisolism, and decreased growth hormone production with 
stunted linear growth (Chua et al., 1996). The first human LEPR mutation was discovered 
in a consanguineous family of Kabylian origin (northern Algeria) where three siblings 
had morbid obesity since early childhood (Clement et al., 1998). This LEPR gene 
mutation resulted from G to A substitution at the +1 position of intron 16 (one base after 
exon 16), which led to exon skipping and loss of transmembrane and cytoplasmic 
domains. The truncated protein might be secreted as a leptin binding protein (like the 
short isoform) which trapped serum leptin in bound form and prolonged its half-life, 
contributing to the very high leptin levels observed. The homozygous mutation caused 
severe obesity and pituitary dysfunction.  The affected sisters had normal birth weight but 
rapidly gained weight in the first few months of life.  Manifestations included bizarre 
eating behaviour, fighting for food, impulsivity and stubbornness, labile emotions and 
social dysfunction, reminiscent of the Prader-Willi Syndrome. However, they were not 
mentally retarded, and had resting metabolic rates similar to that predicted, with normal 
core temperature.  Growth hormone and thyrotropin levels were low, with the presence of 
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hypogonadotropic hypogonadism.  These findings supported leptin and its receptor as 
important physiological regulators of several endocrine functions. 
 
Farooqi et al screened the LEPR genes of 300 subjects with severe early onset 
obesity and hyperphagia, inclusive of 90 probands from consanguineous families, and 
reported seven homozygotes and one compound heterozygote for nonsense or missense 
LEPR mutations which resulted in impaired receptor signaling (Farooqi et al., 2007). 
Affected subjects also had delayed puberty due to hypogonadotropic hypogonadism.  
Unexpectedly, serum leptin levels were within the range predicted by the elevated fat 
mass in these subjects. Thus serum leptin levels cannot be used as a marker for leptin 
receptor deficiency. The clinical features of leptin receptor-deficient subjects were less 
severe than those with congenital leptin deficiency.  
 
Inspiration of the present study        
The discovery of leptin and its receptor heralded a new era in obesity research, as it 
inspired an unprecedented surge of research activities leading to an explosion of new 
knowledge about the intricate molecular mechanism of weight regulation. These research 
efforts further established leptin as the key long term regulator of the biological weight 
regulation mechanism and the hormonal link between adipocyte and the brain. The 
melanocortin system downstream of leptin became the focus of research efforts in the 
past decade. The phenotypic similarity between murine and human forms of leptin and 
leptin receptor deficiencies demonstrated the high conservation of weight regulation 
mechanism across species, and supported the applicability of knockout mouse models 
  20
deficient in candidate genes or molecules predicted to participate in energy regulation in 
the study of human energy homeostasis. The flurry of research activities which generated 
knockout obese mouse models also saw a corresponding rise in reports of human obesity 
due to single gene defects affecting the melanocortin system, with striking resemblance 
to the murine forms. These monogenic forms of human and murine obesity validate the 
melanocortin system and its key molecules as an integral part of the weight regulation 
mechanism, as deficiencies of these critical molecules due to the genetic defects lead to 
unequivocal obesity as the predominant phenotypic feature. The subsequent chapters give 
a detailed account of our contribution to this field of obesity research, not only in the 
discovery of novel MC4R mutations causing monogenic human obesity, but also the role 
of genetic variants of POMC and MC3R in the pathogenesis of common obesity.    
 
 The research work on MC3R and MC4R genes were performed in Singapore using 
a local cohort of severely obesity children. The research on POMC gene was performed 
in Cambridge, United Kingdom, in the laboratory of Professor Steve O’Reilly and Dr 
Sadaf Farooqi, using the DNA biobank of their Genetics of Obesity Study (GOOS) 
cohort.   The NMR study decribed in chapter 3 was performed by Dr Glenn Millhauser 
and his team from the University of California, Santa Cruz, California.  Also in the same 
chapter, genotyping of the Tyr221Cys variant in UK cohort of the EPIC-Norfolk study 
using Taqman was performed by Matthew Sims and team from the MRC Epidemiology 
Unit, Cambridge, UK.  Genotyping of Tyr221Cys variant in the French obese cohort 
using FRET based assay was performed by David Meyre and team from the Institute of 
Biology, Pasteur Institute, Lille, France and Section of Genomic Medicine and Genome 
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Centre, Imperial College London, UK. The metabolic labelling and western blot studies 
of Chapter 4 were performed by Assoc Professor John WM Creemers from the 
University of Leuven, Belgium. The α-MSH immunoassay described in chapter 4 was 






Novel Melanocortin 4 Receptor Gene Mutations in Severely Obese Children 
Summary 
Melanocortin 4 receptor (MC4R) deficiency is the commonest monogenic form of obesity. 
The significance of MC4R mutations in Asian obese populations has not been adequately 
examined. The objective of this study is to determine the role of MC4R mutations in 
severely obese Asian children. We screened 227 obese local children and adolescents for 
MC4R gene mutations by polymerase chain reaction (PCR) and direct sequencing. We 
identified three mutations in three subjects: 4 bp deletion from nucleotides 631-634 (c.631-
634delCTCT), Tyr157Ser (c.470A>C), and 1 bp deletion at nucleotide 976 (c.976delT) 
(1.32% of study subjects). The latter two mutations are novel. The Tyr157Ser mutation was 
not found in 188 non-obese controls using restriction enzyme digest analysis. In vitro 
transient transfection studies supported the pathogenic role of both novel mutations 
Tyr157Ser and c.976delT, where the signalling activities of the mutant receptors were 
impaired. Heterozygous MC4R mutations were associated with early onset severe obesity, 
and homozygosity of the MC4R mutation Tyr157Ser resulted in morbid obesity.  MC4R 
mutations result in an autosomal codominant form of obesity with variable expressivity. 
MC4R deficiency is not as common among the obese children in this study compared to 
other populations. Family studies revealed that adults heterozygous for the mutations were 
less obese compared to the children. We hypothesise that this may be due to amelioration 
of phenotype severity with age, genetic anticipation, or difference in exposure to modifying 




The human melanocortin 4 receptor (MC4R) is a 332 amino acid protein encoded by a 
single exon localised on chromosome 18q22 (Gantz et al., 1993b; Sundaramurthy et al., 
1998). The MC4R is a seven transmembrane G-protein coupled receptor highly expressed 
in hypothalamic nuclei which regulate energy homeostasis (Mountjoy et al., 1994; 
Mountjoy and Wild, 1998). MC4R is modulated by the endogenous agonist α-melanocyte 
stimulating hormone (MSH) and antagonist agouti-related protein, and signals through 
activation of adenylate cyclase (Schwartz et al., 2000). Mice with inactivation of both 
copies of the MC4R genes produced an obesity syndrome with hyperphagia associated 
with pathological lack of satiety, hyperinsulinaemia with hyperglycaemia, and increased 
linear growth, but unlike leptin deficient mice, had normal reproductive function (Huszar 
et al., 1997). Heterozygotes had an intermediate weight between the homozygotes and 
wild-type mice, and females were more affected than males. MC4R knockout mice 
continue to increase feeding on a high fat diet, but do not increase thermogenesis.  
Interestingly, the MC4R knockout mouse exhibits normal feeding and returns to previous 
weight in response to food restriction.  Thus MC4R does not appear to be required for 
normal feeding or metabolic response to fasting.  However, MC4R is required for normal 
response to high fat diet by maintaining satiety, and increasing thermogenesis and 
metabolic rate.  
 
MC4R deficiency resulting from disruption of one or both MC4R alleles 
represents the commonest monogenic form of human obesity (Farooqi et al., 2003; 
Vaisse et al., 2000). Obese individuals with MC4R deficiency displayed a common, non-
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syndromic form of obesity and were not characterized by any peculiar phenotypic 
abnormalities. The subjects with MC4R mutations were obese from an early age, but with 
increase in both fat and lean masses, were excessively hungry from 6-8 months of age 
with persistent food-seeking behaviour, and become distressed if food was not provided. 
They had higher food intake when compared to obese controls when assessed with ad-
libitum meals. There was increased growth velocity in childhood, where those with 
MC4R mutations were taller than matched obese controls, and the bone age exceeded the 
chronological age by 1 to 4.9 years.  Pubertal onset and secondary sexual characteristics 
were normal.  They also had significantly higher insulin levels compared to matched 
controls, but the majority were not diabetic.  The proportions of type 2 diabetic or 
glucose intolerant subjects, triglyceride levels, and leptin levels were not statistically 
different between both mutated and non-mutated obese groups. The affected subjects did 
not have any developmental, intellectual or behavioural problems, and there were no 
dysmorphic features.   
 
 In-vitro function of mutant MC4-receptors correlated with the severity of the 
clinical phenotype, indicating that weight regulation is sensitive to amount of functional 
MC4 receptors. Subjects with inactivating (null) MC4R mutations were heavier, taller, 
and more hyperphagic than those with partially active MC4R mutations (Farooqi et al., 
2003). 
 
Most family studies revealed autosomal co-dominant pattern of inheritance. 
Homozygotes for MC4R mutations exhibited a more severe phenotype than heterozygotes, 
where they were heavier and taller. Transmission of the mutations in the affected families 
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indicated variable penetrance and expressivity that is not related to the functional severity 
of the mutations in-vitro.  Family studies of heterozygous probands demonstrated co-
segregation of mutation with early onset obesity with 100% penetrance, while that of 
homozygous probands demonstrated early onset obesity only in 68% of heterozygous 
family members. There is variable age of onset of obesity as well as its severity, even for 
the same mutation within the same family. The reason for this variability in penetrance 
and expressivity is yet to be fully elucidated.   
 
Human MC4R deficiency was reported to affect 4 and 5.8 % of severely obese 
French and British populations respectively (Farooqi et al., 2003; Vaisse et al., 2000). 
However, studies elsewhere reported low incidence of MC4R mutations in their 
respective obese populations (Adams et al., 2007; Hinney et al., 2003; Jacobson et al., 
2002; Larsen et al., 2005; Miraglia Del Giudice et al., 2002; Ohshiro et al., 1999; Rong et 
al., 2006; Wang et al., 2006). The prevalence and spectrum of MC4R mutations in the 
obese Asian populations has not been well studied. Therefore, we embarked on a study to 
determine the role of MC4R mutations in Singapore’s obese paediatric population (Lee et 
al., 2007a).  
 
Subjects and Methods 
Study Subjects 
The MC4R gene was analysed in 227 unrelated children and adolescents with early onset 
severe obesity (149 boys and 78 girls; 116 Chinese, 82 Malays, 22 Indians, 7 others).  The 
mean (standard deviation) age was 10.9 (3.3) years, BMI 32.1 (5.5) kg/m2, WFH 170 (22) 
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%, and all subjects developed obesity before the age of 10 years.  These children were 
recruited mainly from the nationwide school health clinic, a primary healthcare service and 
facility which routinely screens schoolchildren.  Consecutive patients who met the 
inclusion criteria were invited to participate in the study.   The inclusion criteria were 
severe obesity with body weight at least 140% of ideal weight for height (WFH) based on 
local chart, and onset of obesity before 6 years of age. We recruited young children who 
develop severe early onset obesity in an attempt to increase the likelihood of identifying 
children who are genetically predisposed to obesity, as we hypothesized that genetic factors 
rather than the environment play a predominant pathogenic role in these individuals. As a 
local BMI chart for children was not available at the time of the study, WFH was used as 
an acceptable alternative measure of obesity (Mei et al., 2002).  This research was 
approved by the Research and Ethics Committee of the National University Hospital, and 
informed written consent was obtained from all subjects and parents.   
 
Metabolic / Endocrine Tests and Body Composition Assessment 
Blood samples were obtained from the obese subjects in the fasted state for biochemical 
profiling, including venous glucose for oral glucose tolerance test (OGTT), fasting serum 
C-peptide (CP) and insulin (Ins) levels. Insulin resistance was calculated using the 
homeostasis model assessment (HOMA) (Matthews et al., 1985). Bone mineral density of 
the second to fourth lumbar spine and body fat composition were assessed using Dual 
Energy X-ray Absorptiometry (DEXA) (Norland DEXA model XR-36, Fort Atkinson, 




Genomic DNA extracted from peripheral leukocytes was analysed. The single exon of 
MC4R gene was amplified by PCR using the following primers: Forward primer 5’-
GAGAACAAGAAAGCAAAGAGCAG-3’, and reverse primer 5’-
TACCCTACACGGAAGAGAAAGC-3’. Amplification was carried out for 35 cycles. 
Each cycle consisted of a 45 seconds denaturing step at 95oC, a 45 seconds annealing step 
at 55oC, and a 1 minute extension step at 72oC. Prior to the 35 cycles, the sample was kept 
at 95oC for 3 minutes for denaturation. After the 35 cycles, there was a final elongation 
phase at 72oC for 5 minutes. The size of the amplicon was 1374 bp. The amplicons were 
directly sequenced in 2 fragments using the following sequencing primers: 5’-
TGGAGGAAATAACTGAGACG-3’ and 5’-TGTCATCATCTGCCTCATC-3’. Novel 
sequence variants were confirmed by reverse sequencing. Heterozygous frameshift 
mutations were also reconfirmed by cloning each of the two alleles from each affected 
subject into pDrive vectors followed by direct sequencing (see “PCR and Cloning” below). 
Sequencing was performed using BigDye v2.0 Terminator Cycle Sequencing Kit (PE 
Applied Biosystems) and analysed on the ABI Prism 3100 Genetic Analyzer.  
 
 A potentially novel missense MC4R mutation Tyr157Ser was found during the 
screening process. 188 genomic DNA samples from 99 healthy children with normal height 
and weight [mean age (SD) = 7.1 (4.6) years; mean body mass index (BMI) (SD) = 16.8 
(3.4) kg/m2; 63 males & 36 females; 61 Chinese, 20 Malays, 18 Indians] and 89 DNA 
samples from healthy adults (BMI < 25 kg/m2; 30 males, 59 females; 27 Chinese, 30 
Malays, 32 Indians) were analysed as normal controls. Restriction enzyme Rsa I was used 
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to detect MC4R mutation Tyr157Ser in 188 control samples and the family members of the 
proband. Using primers which amplified the wild-type MC4R gene between nucleotide 
positions 811 and 1120, the resultant PCR product had two Rsa I recognition sites at 
nucleotide positions 834 and 861, yielding three fragments with Rsa I digest, one of which 
is 259 bp. Using the same primers to amplify the mutant MC4R gene Tyr157Ser, there is 
only one Rsa I recognition site at nucleotide position 861 on the mutant amplicon, 
producing only two fragments, one of which is 286 bp. Electrophoresis using 
polyacrylamide gel was able to differentiate the 259 bp and 286 bp fragments, thus 
identifying the mutant from wild-type alleles. Primers for PCR-digest technique: forward 
primer 5’-CTGCTTTCAATTGCAGTGGA-3’, reverse primer 5’-
ATGGTCAAGGTAATCGCTCC-3’. PCR conditions: denaturation at 95oC for 3 minutes, 
followed by 35 cycles of denaturation at 95oC for 45 seconds, annealing at 54oC for 45 
seconds, elongation at 72oC for 45 seconds, followed by final elongation at 72oC for 5 
minutes.  
 
In vitro Receptor Function Studies 
PCR and Cloning 
Wild-type and mutant MC4R were directly amplified from DNA of normal and affected 
subjects. The forward and reverse primers contain Kpn I and Xho I restriction sites 
respectively: MC4R-F (5’GGTACCATGGTGAACTCCACCCACCG3’), MC4R-R 
(5’CTCGAGTTAATATCTGCTAGACAAGT3’). The amplicons were cloned into the 




The MC4R gene was excised with Kpn I and Xho I restriction enzyme and 
subcloned into the pBudCE4 mammalian dual expression vector (Invitrogen Corp) under 
the control of EF-1α promoter. The synthetic cDNA sequence encoding Renilla 
luciferase enzyme was excised from the phRG-TK vector (Promega Corp, Wisconsin, 
USA) with Hind III and BamH I, and subcloned into the above pBudCE4/MC4R 
construct under the control of the CMV promoter. All constructs were sequenced for 
verification.  
 
HEK 293 cells were maintained in DMEM (Sigma) supplemented with 10% FBS, 
100 U/mL penicillin G, 100 mcg/mL streptomycin sulfate and 250 ng/mL amphotericin B 
(Sigma). Cells were incubated at 370C in humidified air containing 5% CO2.  
 
Transient Transfection Study  
Transient transfections were performed using Effectene reagent (Qiagen GambH, Hilden, 
Germany) according to the manufacturer’s recommendation. The cAMP responsive 
firefly luciferase vector, pCRE-Luc (Stratagene, California, USA) was transiently co-
transfected in HEK 293 cells with the construct expressing the wild-type or mutant MC4 
receptors and Renilla luciferase (pBudCE4/Renilla/MC4R) in a 9:1 ratio. After 24-hour 
incubation, transfected cells were washed once with 1x PBS and fresh media were added 
with serial dilutions of α-MSH ranging from 1 pM to 10 uM, and the generation of 
cAMP was assayed through the activation of co-transfected pCRE-Luc. The data was 
expressed as ratio of firefly luciferase activity to Renilla luciferase activity (relative light 
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units) to normalize for transfection efficiency and amount of MC4R produced. Cells 
expressing only pCRE-Luc and pBudCE4/Renilla construct were used as negative 
controls. Each dilution was performed in triplicates, and incubated for a further 24-hour 
period prior to cell lysis and luciferase readings.   
 
Both firefly and Renilla luciferase activities were determined using the Dual 
Luciferase Reporter Assay System (Promega Corp, Wisconsin, USA) in a TD-20/20 
(Turner Designs) luminometer as recommended by the manufacturer. 
 
Statistical analysis 
Graph fit curves and EC50 were obtained and performed using GraphPad Prism 4 for 
Windows (version 4.02 GraphPad software, San Diego, California, USA), and curves were 
fitted using the logistical equation.   
 
Results 
From the 227 obese subjects studied, we identified three mutations in three unrelated 
subjects: a missense mutation Tyr157Ser (c.470A>C) in homozygosity; a heterozygous 
mutation with T deletion at nucleotide position 976 (c.976delT); a heterozygous mutation 
with 4 bp deletion of nucleotides 631-634 (c.631-634delCTCT); the former two mutations 
are novel. A single nucleotide change from A to C at nucleotide position 470 resulted in the 
substitution of hydrophobic tyrosine by hydrophilic serine at codon 157 (Tyr157Ser) 
(figure 2-1A), located at the second intracytoplasmic loop of the transmembrane domain. A 
deletion of T nucleotide at position 976 of the coding region led to a frameshift which 
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resulted in readthrough of the stop codon, followed by an out-of-frame stop codon situated 
63 nucleotides downstream at nucleotide position 1062. While the wild-type MC4R protein 
sequence ended at residue 332, the resultant mutant receptor is predicted to be a longer 
polypeptide chain with 28 aberrant amino acid residues from codon 326, an extra 21 amino 
acids longer than the wild-type MC4R (Figure 2-1B). The third MC4R mutation c.631-
634delCTCT involved four base pairs deletion (CTCT) at nucleotide position 631-634, or 
at codon 211 (figure 2-1C). This mutation results in a frameshift that introduces five 
aberrant amino acids culminating in a premature stop codon (Met-Ser-Thr-Cys-Ser-X) in 
the region encoding the fifth transmembrane domain, thus leading to a truncated protein 
which would likely result in a non-functional receptor.     
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 Figure 2-1A. Sequencing of the MC4R gene in a proband revealed A to C transition in 
homozygosity at nucleotide position 470 (arrow), leading to the substitution of tyrosine by 




Figure 2-1B. A deletion of T nucleotide at position 976 of the coding region (marked by a 
star sign in wild-type MC4R sequence) resulted in the heterozygous frameshift mutation 
found in the second proband; the arrows indicate the starting point of the deletion., this 
single base pair deletion resulted in 28 aberrant amino acid residues from residue 326 
onwards (in italics and underlined), 21 residues more than the wild-type sequence. 
 
 
residue 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353  
mutant Thr Gln Tyr Arg Asn Met His Lys Arg Leu Phe His Ser Tyr Pro Thr X 
residue 324 325 326 327 328 329 330 331 332 333 334 335 336 337 
Wild-type Gly Leu Cys Asp Leu Ser Ser Arg Tyr X     
mutant Gly Leu Val Thr Cys Leu Ala Asp Ile Lys Trp Gly Gln Ser 
T G T G AC T  T G T  C  T AG C A G  
G T G AC T T  G T C  T  AG C A G A 
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Figure 2-1C. The MC4R sequence of the third proband revealed deletion of 4 base pairs at 
nucleotide position 631 to 634 in heterozygosity (affecting codon 211). The 4 base pairs 
deleted were CTCT (as underlined in the wild-type sequence), and the arrows indicate the 
starting point of the deletion. This frameshift mutation resulted in 5 aberrant amino acid 









residue 206 207 208 209 210 211 212 213 214 215 216 217 218 219……. 
Wild-type Ala Leu Met Ala Ser Leu Tyr Val His Met Phe Leu Met Ala ….... 
mutant Ala Leu Met Ala Ser Met Ser Thr Cys Ser X    
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Impaired signaling properties of the two novel mutant receptors (Tyr157Ser and 
c.976delT) 
 The two mutant MC4 receptors resulting from the mutations Tyr157Ser and 
c.976delT demonstrated significantly reduced signaling activity compared to wild-type 
MC4 receptors (Figure 2-2). The c.631-634delCTCT mutation was described previously 
(Farooqi et al., 2000; Hinney et al., 1999; Yeo et al., 1998), and receptor function studies 
had shown that this mutant receptor was non-functional (Farooqi et al., 2000).   
 
Clinical characteristics of subjects with mutations 
Tyr157Ser  The novel MC4R mutation Tyr157Ser was found in homozygosity in a 9-year-
old Indian boy with consanguineous parents (first cousins) (Figure 2-3A). His parents, 
younger sister and younger brother were heterozygotes (Figures 2-3A and 2-4). This 
mutation Tyr157Ser was not found in 188 DNA samples from non-obese individuals 
(normal controls) (Figure 2-4A). The genotype and phenotype of the family members are 
described in figure 2-3A.  All the heterozygous family members were obese, but the 
homozygous proband was more severely affected, demonstrating an additive effect. The 
proband homozygous for the mutation was afflicted with more obesity-related 
complications compared to the other heterozygous family members, with severe bilateral 
genu varus (Figure 2-4B), moderate obstructive sleep apnoea, higher insulin resistance and 
eventually diabetes mellitus. Weighing 3.25 kg at birth, the proband was progressively 
overweight since 6 months of age, gaining weight at about 10 kg per year, and was 80.5 kg 
by 6 years of age. When he presented at 8.8 years old, he weighed 92.4 kg with body mass 
index (BMI) of 44 kg/m2 and percentage ideal weight for height of 231%. 
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Figure 2-2. Constructs with wild-type and mutant MC4R were co-transfected with pCRE-
Luc into HEK293 cells and stimulated with varying amounts of α-MSH. Y axis represents 
the fold increase over basal Relative Light Units (RLU), which was the ratio of 
luminescence generated by Firefly luciferase (from pCRE-Luc) to Renilla luciferase (from 
pBudCE4/Renilla/MC4R construct); the data was expressed as such to normalise for 
transfection efficiency and amount of MC4R produced. This represented the amount of 
cyclic AMP generated with increasing concentration of the ligand α-MSH (represented by 
x-axis). Each data point represented the mean and standard error range of 3 independent 
experiments performed in triplicates. Compared to the wild-type, there was statistically 
significant reduction in signaling activity of the Tyr157Ser and c.976delT mutant MC4 
receptors. Maximum fold activity: wild-type 7.677 (95% C.I. 7.117 - 8.237), Tyr157Ser 
5.633 (95% C.I. 4.695 to 6.571), c.976delT 5.214 (95 % C.I. 4.824 to 5.604);  
EC50: wild-type 5.747 x10-9 (95% C.I. 3.66 x10-9 - 9.024 x10-9), Tyr157Ser 9.954 x10-8 
(95% C.I. 6.167 x10-8 - 1.607 x10-7), c.976delT 6.581 x10-9 (95% C.I. 4.077 x10-9 - 1.062 
x10-8)    
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He was tall for his age with height standard deviation score (SDS) of +2.8, and elevated 
fasting insulin level 25 mU/L, but he did not have glucose intolerance then. His 24 hours 
urinary cortisol levels were normal, diurnal rhythm of his cortisol secretion was intact, and 
was suppressible with low dose dexamethasone suppression test. He used to swim, but had 
stopped as he was limited by the genu varus. His estimated caloric intake was 2379 
kcal/day, with 22% from fats, 18% from proteins and 60% from carbohydrates. At 11.5 
years of age, he was in early puberty (Tanner stage 2) and weighed 130 kg with BMI of 
51.9 kg/m2 and WFH 260%. At 11 years 8 months, he was diagnosed to have type 2 
diabetes mellitus confirmed with two separate oral glucose tolerance tests and an elevated 
glycated haemoglobin level of 7.4%. His diabetes control was poor and, coupled with poor 
dietary control, required insulin shortly after diagnosis. Currently at 13 years old, his 
diabetes control continued to be poor with HbA1c levels ranging from 9% to 13.5%.  
 
 His father had high cholesterol and triglyceride levels despite lower adiposity and 
insulin resistance. The proband and his father were relatively inactive, and did not engage 
in regular physical activity. His mother had gestational diabetes during all her pregnancies, 
but did not develop diabetes mellitus post-partum. She was heaviest at 21 years of age 
weighing 107 kg, but had since lost some weight (currently 96 kg) through dieting and 
exercise. His father’s heaviest weight recorded was 90.1 kg.   
 
c.976delT 
The proband is a Chinese boy who was born at term with birth weight of 3.1 kg, 
and was noted to be overweight since infancy. When he presented at 7.9 years, he was 
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severely obese with borderline hyperlipidaemia, but no glucose intolerance (Figure 2-3B 
and Table 2-1). At 12.8 years of age, his WFH increased to 189% and BMI was 37 kg/m2. 
His father is heterozygous for the mutation and was obese as a child, but not as severely 




An obese 16-year-old Malay female subject was heterozygous for this mutation 
(Table 2-1 and figure 2-3C). She weighed 73 kg with WFH 162% and %BF 44.1% when 
she presented with type 2 diabetes mellitus and hypercholesterolemia. She was born at 
term with birth weight of 2.58 kg.  She was obese before 10 years of age and presented at 
16 years of age with polydipsia and polyuria. Her fasting glucose was elevated at 17.2 
mmol/L and HbA1c was 10.3%. Only the proband and her mother were genotyped 
(Figure 2-3C). Her father also had type 2 diabetes and weighed 100 kg. As her mother did 
not carry the mutant allele, we inferred that the mutant allele was inherited from her 
father. At 22 years of age, she weighed 80 kg with WFH still at 160%. Her diabetes 
control had been poor due to poor compliance. Her recent HbA1c was 8.3% on a 
combination of metformin, glipizide and repaglinide. She recently developed diabetic 
nephropathy with significant albuminuria (1484 mg/day) and was treated with enalapril.      
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Figure 2-3. Family pedigrees with MC4R mutations. The age (in years), body mass index 
(*), percentage body fat (+), percentage ideal weight for height (^), and genotypes are 
listed. N represents the normal MC4R allele, and M represents the mutant MC4R allele 








Figure 2-4 A. PCR-digest method to screen for Tyr157Ser mutation. Control samples (C) 
with wild-type alleles would yield 259 bp fragment, while that of the proband (P) who was 
homozygous for the Tyr157Ser mutation would produce 286 bp fragment; those of the 
family members heterozygous for the mutation would produce both fragments (F=father, 
M=mother, S=sister). The younger brother was subsequently genotyped by direct 
sequencing and confirmed to be heterozygous for this mutation. B. The homozygous 
proband (13 years old) with his younger sister (8 years old) and younger brother (4.5 years 
old), who were both heterozygous, demonstrating the additive effect of this mutation on the 






























Table 2-1. The serial anthropometric measurements, insulin, C-peptide, HOMA, bone 
density and percentage body fat (when available) of four young MC4R mutation carriers. 
 
 















Age (years) 10.9 + 3.3 (2.0-19.0) 8.8 11.5 3.5 8.1 7.9 12.8 16.3 22 
BMI (kg/m2) 32.1 + 5.5 (22.8-53.9) 44.0 51.9 21.0 26.8 31.0 37 31.4 32 
WFH (%) 170 + 22 (128-273) 
 
231 260 140 167 177 189 162 160 
Height standard 
deviation score 
1.44 + 1.15 (-1.59-
5.89) 
2.84 1.9 1.38 1.07 2.10 1.8 -0.05 0.02 
Fasting glucose 
(mmol/L) 
4.8 + 1.8 (3-16.3) 4.4 5.6 4.3 4.0 4.4 - 10.5 - 
Fasting Insulin 
(mU/L)  
36.6 + 45.3 (2.5-
539.0) 
25.4 77.3 7.7 17.2 27.1 - 37.4 - 
Fasting C-Peptide 
(pmol/L)  (NR:298 
– 1324)  
1324 + 806 (312-
5602) 





7.67 + 9.61 
(0.57 – 110.20) 
4.97 19.24 1.47 3.06 5.39 - 17.45 - 
Percentage body 
fat by DEXA (%) 
40.4 + 5.0 (26 – 54) 48.4 41 53 40 39.0 - 40 - 
Lumbar spine bone 
density (g/cm2) / z 
score  
0.77 + 0.12 (0.2–1.36) 
/ 0.64 + 0.64 (-0.55–
3.41) 
0.71 / 1.36 0.99 / 1.63 0.56 / 
2.31 
0.68 / 1.2 0.61/0.20 - - - 
 
Values expressed as mean + SD (range); NR= normal range 
N represents the normal MC4R allele, and M represents the mutant MC4R allele. 
TΔ = c.976delT 




















The missense mutation Tyr157Ser is a rare variant not found in our control samples, and 
it resulted in substitution of tyrosine residue by serine at codon 157, which is located at 
the second intracytoplasmic loop of the transmembrane domain. The transmembrane 
domain directly interacts with G proteins and controls cyclic adenosine monophosphate 
(cAMP) production, and thus we postulate that this mutation may interfere with G-
protein interaction, leading to reduced cAMP generation. Tyrosine at codon 157 is a 
highly conserved residue present in the MC4R sequence of many other species, from 
teleost fish through to mammals (accession numbers: Zebrafish NP_775385, Chicken 
NP_001026685, Mouse NP_058673, Rat NP_037231, Human NP_005903). The 
c.976delT mutation resulted in an abnormal MC4R protein with aberrant amino acid 
residues from codon 326, located in the intracellular domain. The c.631-634delCTCT 
mutation led to a frameshift that introduces five aberrant amino acids culminating in a 
premature stop codon in the region encoding the fifth transmembrane domain, thus 
resulting in a truncated protein, if the mRNA is stable enough for translation in vivo. 
These three mutations resulted in mutant MC4 receptor proteins which had reduced 
signaling activity in vitro. The pathogenic role of these mutations are further supported 
by the family studies which demonstrated cosegregation with the obese phenotype, and 
also an additive effect whereby the homozygosity of the Tyr157Ser mutation resulted in a 
more severe obese phenotype compared to the heterozygotes. We recognized that more 
family members should be studied to draw firm conclusions about the mode of 




The prevalence of pathogenic MC4R mutations reported in various obese 
populations varied widely, ranging from 0.5 to 5.8% (Farooqi et al., 2003; Hinney et al., 
2003; Jacobson et al., 2002; Larsen et al., 2005; Miraglia Del Giudice et al., 2002; 
Ohshiro et al., 1999; Rong et al., 2006; Vaisse et al., 2000; Wang et al., 2006). One 
possible explanation is differences within the study cohort in terms of ethnicity, age of 
onset, and severity of obesity. A British study of about 500 subjects with early onset 
severe obesity reported the highest prevalence of 5.8% (Farooqi et al., 2003), while a 
French study of adults with severe obesity where a third were obese since childhood, 
yielded a prevalence of 4% (Vaisse et al., 2000). However, a German cohort of extremely 
obese children found only 1.9% (Hinney et al., 2003), and an Italian study of 208 children 
with severe early onset obesity found only one patient with a pathogenic MC4R mutation 
(<0.5%) (Miraglia Del Giudice et al., 2002). The significance of MC4R mutations in 
Asian obese populations has not been adequately examined. A small Japanese study of 50 
obese adults revealed no pathogenic mutations (Ohshiro et al., 1999), while two studies 
involving Chinese adult and paediatric subjects identified a few mutations of uncertain 
significance in less than 1.5% of the cohort (Rong et al., 2006; Wang et al., 2006). 
Despite recruiting only children and adolescents with early onset severe obesity similar to 
those of other studies (Farooqi et al., 2003; Vaisse et al., 2000), our study found only 
three mutations in three subjects (1.3%). Taken together with the results of other studies, 
it is unlikely that the higher prevalence reported in some cohort studies were due to 
selection of study subjects with early onset severe obesity, but rather that MC4R 
mutations are truly more prevalent in northern European obese populations (Farooqi et al., 
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2003; Vaisse et al., 2000).  We recognized that the ethnic heterogeneity of our study 
population would be inadequate to estimate the true frequency of MC4R mutations for the 
various ethnic groups (Malays and Indians especially) and limit the comparision to other 
studies of homogeneous populations.  Nevertheless, our study gave an estimate of the low 
prevalence of MC4R mutations in this part of the world.  Our Chinese subgroup was 
fairly large (n=116), and the low prevalence (0.9%) was consistent with that reported in 
other studies of Chinese subjects (Rong et al., 2006; Wang et al., 2006).   
 
Though there were a few common mutations described across populations, such 
as the c.631-634delCTCT mutation in our Malay subject which was previously reported 
in English and German Caucasian subjects (Hinney et al., 1999; Yeo et al., 1998), a 
significant number of novel and ‘exclusive’ or ‘private’ mutations were reported in 
different obese populations from various parts of the world, and these mutations were not 
frequent even within these populations (Farooqi et al., 2003; Hinney et al., 2003; Hinney 
et al., 1999; Jacobson et al., 2002; Larsen et al., 2005; Miraglia Del Giudice et al., 2002; 
Ohshiro et al., 1999; Rong et al., 2006; Vaisse et al., 2000; Wang et al., 2006). One 
possible reason for this relative lack of founder effect is that the pathogenicity of MC4R 
mutations in obesity may be a fairly recent event in human evolution.   
 
 Our family studies revealed variable phenotype and it appeared that the children 
and younger subjects were more severely affected compared to the adults / parents. At least 
two large studies have shown incomplete penetrance and variable expressivity in their 
cohort of MC4R mutation carriers (Hinney et al., 2006; Vaisse et al., 2000). Heterozygous 
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mc4r+/– mice also display a broad variability in phenotype with an adult weight ranging 
from that of wild-type to that of homozygous mc4r–/– mice (Huszar et al., 1997). This is not 
surprising, considering that the obese phenotype is also dependent on the environment, 
behaviour, and other modifier genes. The current environment may be more ‘obesogenic’ 
compared to that of the previous generation, and exposure to disease modifying factors 
such as the environment at critical stages of childhood may determine the eventual 
phenotype. A second possible reason is genetic anticipation, where the next generation is 
more affected. Another possibility is amelioration of phenotype as the young mutation 
carriers become adults. Young British subjects with MC4R mutations were described to 
have early onset hyperphagic obesity, higher lean body mass, increased linear growth with 
higher height SDS scores, hyperinsulinaemia and higher bone mineral density compared to 
matched obese controls, and amelioration of hyperphagia and degree of hyperinsulinaemia 
observed in adulthood (Farooqi et al., 2003). Our follow up observation of several young 
MC4R mutation carriers revealed increasing WFH during childhood and the early pubertal 
years serially, and perhaps even insulin levels and insulin resistance indices were rising, but 
their percentage body fat, and height standard deviation scores were decreasing (Table 2-1). 
The trend in bone mineral density changes was not discernible. Our young subjects with 
heterozygous MC4R mutations did not demonstrate a clear increase in insulin resistance 
compared to obese matched controls, except for proband with c.631-634delCTCT who 
presented with glucose intolerance (table 2-2) (unable to find matched controls of proband 
homozygous for Tyr157Ser).   Unfortunately, the small number of mutation carriers in our 
cohort precluded any meaningful interpretation. Large studies such as those in the UK, 
France and Germany with high numbers of MC4R mutation carriers will be able to provide 
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valuable insights on the natural history of the MC4R mutant phenotype with follow up 
studies of their young subjects as they mature into adulthood.  
   
Table 2-2.  HOMA, percentage body fat, and BMI of three subjects heterozygous for 
MC4R mutations compared to obese controls matched for age (± 1.5 years), gender, 
ethnicity, and WFH (± 10%). 
 
 Sister  

















Age (years) 8.1 8.4 (0.8) 7.9 8.7 (0.5) 16.3 16.3 (0.5) 
BMI (kg/m2) 26.8 27.4 (2.4) 31.0 31.3 (0.8) 31.4 33.4 (2.4) 




(HOMA) (NR <2) 
3.06 8.97 (4.5) 5.39 5.06 (0.71) 17.45 6.85 (4.4) 
Percentage body 
fat by DEXA (%) 
40 47.2 (1.4) 39.0 41.6 (1.2) 40.0 39.1 (1.4) 
 
Values expressed as mean (SEM) 
N represents the normal MC4R allele, and M represents the mutant MC4R allele. 
TΔ = c.976delT 
CTCTΔ = c.631-634delCTCT  
 
 
The data in this chapter is published in: Lee YS, Poh LK, Kek BL, and Loke KY (2008). 




A POMC variant implicates β-melanocyte-stimulating hormone in the control of 
human energy balance 
Summary 
The MC4R plays a critical role in the control of energy balance. Of its two pro-POMC-
derived ligands, α- and β-MSH, the majority of attention has focused on α-MSH, partly 
reflecting the absence of β-MSH in rodents. We screened the POMC gene in 538 patients 
with severe, early-onset obesity and identified five unrelated probands who were 
heterozygous for a rare missense variant in the region encoding β-MSH, Tyr221Cys. This 
frequency was significantly increased (p < 0.001) compared to the general UK Caucasian 
population and the variant cosegregated with obesity/overweight in affected family 
members. Compared to wild-type β-MSH, the variant peptide was impaired in its ability 
to bind to and activate signaling from the MC4R. Obese children carrying the Tyr221Cys 
variant were hyperphagic and showed increased linear growth, both of which are features 
of MC4R deficiency. These studies support a role for β-MSH in the control of human 
energy homeostasis.  
Introduction 
The pro-opiomelanocortin (POMC) gene is expressed in neurons originating in the 
arcuate nucleus of the hypothalamus and in the nucleus tractus solitarius (NTS) of the 
caudal medulla, as well as in the corticotrophs of the anterior pituitary and in the skin and 
lymphoid system (Hadley and Haskell-Luevano, 1999). The human POMC gene is 
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located on chromosome 2p23.3 and spans 7665 kb. It comprises of 3 exons, and though 
all three exons are transcribed, only part of the mRNA is translated. Exon 1 only contains 
untranslated sequences, part of exon 2 codes for signaling peptide and the first few amino 
acid residues of the N-terminal peptide (NT), and exon 3 codes for most of the translated 
mRNA, namely the C-terminal of NT, joining peptide (JP), adrenocorticotropic hormone 
(ACTH) and β-lipotropic hormone (β-LPH) (figure 3-1). The signaling peptide is 
necessary for the translocation of the nascent protein through the membrane of the rough 
endoplasmic reticulcum (RER), after which it is rapidly cleaved. The POMC protein 
(accession no. NP_000930) is then engaged in the secretory pathway and ready for 
processing by the prohormone convertases 1 & 2 (PC1 & PC2). POMC undergoes 
extensive and tissue-specific posttranslational processing by proprotein convertases (PCs) 
to yield a range of biologically active peptides (Pritchard et al., 2002; Raffin-Sanson et al., 
2003; Seidah and Chretien, 1999).  
 
Pituitary corticotrophs express prohormone convertase 1 (PC1), but not PC2, 
which cleaves 4 specific dibasic Lys-Arg cleavage sites and results in the production of 
NT, JP, ACTH, and β-LPH. In contrast, the expression of PC2 (in addition to PC1) 
within the hypothalamus results in additional processing and cleavage of all dibasic Lys-
Arg and Arg-Arg sites of the precursor polypeptide, leading to the production of α-, β-, 
and γ-MSH (the melanocortins) but not ACTH. The melanocortins mediate their effects 
through a family of five related G protein-coupled receptors, two of which, MC3R and 
MC4R, are highly expressed within the central nervous system (Gantz and Fong, 2003). 
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Genetic defects impairing the synthesis and processing of POMC and in the receptors for 
its constituent melanocortin peptides have clearly established that the melanocortin 
system plays a critical role in energy homeostasis in rodents and humans (Cone, 2005).  
 
POMC mutations have helped to shed light on the role of the melanocortin system 
in energy homeostasis (Coll et al., 2004). Mice (Challis et al., 2004; Yaswen et al., 1999) 
and humans (Farooqi et al., 2006; Krude et al., 1998; Krude et al., 2003) genetically 
lacking POMC-derived peptides are severely obese, and were associated with severe 
glucocorticoid deficiency due to concomitant absence of ACTH. Importantly, 
heterozygous null POMC mutations in mice (Challis et al., 2004) and humans (Krude et 
al., 2003) predispose to obesity but do not necessarily result in a severe or intermediate 
phenotype, and do not exhibit cortisol deficiency. The heterozygous Pomc+/- mice had 
similar phenotype to wildtype mice on standard chow (Challis et al., 2004; Yaswen et al., 
1999), but developed obesity when put on a high-fat diet (Challis et al., 2004), exhibiting 
an intermediate obese phenotype between wild-type and Pomc-/- mice. Heterozygous 
parents of obese children homozygous for POMC null mutations had high normal to high 
BMI (Krude et al., 2003), and other family members heterozygous for POMC null allele 
were more overweight than those with wildtype alleles (Farooqi et al., 2006).  
Heterozygous partially inactivating POMC mutations Arg236Gly were also found more 
frequently in obese children (Challis et al., 2002). Thus it can be inferred that a single 
functional copy of the POMC gene may not be sufficient for maintaining normal energy 
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homeostasis under certain conditions such as in an “obesogenic” environment, and 
haploinsufficiency can interact with dietary factors to increase body weight.   
 
There is still uncertainty regarding the relative importance of particular POMC-
derived melanocortin ligands in the control of energy balance. In vitro studies established 
that α- and β-MSH both bind to the MC4R with high affinity and with similar IC50 values, 
while γ-MSH preferentially binds to MC3R with a 50-fold higher affinity than to MC4R, 
which it binds to poorly (Abbott et al., 2000). Some studies showed that β-MSH has 
higher affinity for MC4R in stably expressing cell lines (Schioth et al., 1996) and in rat 
hypothalamic homogenates (Harrold et al., 2003). Intracerebroventricular (icv) 
administration of β-MSH in rats induced early growth response factor-1 expression in 
hypothalamic nuclei (Millington et al., 2001). Several in vivo studies have demonstrated 
that rodents given a single icv injection of α-MSH display a dose-dependent reduction in 
food intake (Poggioli et al., 1986). In direct comparisons of icv administration of 
melanocortin peptides, β-MSH has been shown to reduce food intake at equimolar doses 
(Abbott et al., 2000). Despite this, attention has been principally focused on α-MSH as 
the probable endogenous ligand in rodents (Mountjoy and Wong, 1997), and presumed to 
be the de facto ligand in the human melanocortin system as well. This is largely because 
rodents (the most common experimental species) lack the proximal dibasic site that is 
necessary for the proteolytic cleavage event that produces β-MSH in humans (mouse 
accession number P01193, rat accession number AAA41903). Thus the role for β-MSH 
in the control of energy balance has been largely overlooked.  
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Common obesity is a polygenic/multifactorial trait, and genetic variations 
affecting molecules of the melanocortin pathway may be contributory genetic factors.  
The region of human chromosome 2 containing the POMC gene has also been identified 
by several studies as a susceptibility locus for common human obesity (Comuzzie et al., 
1997; Hager et al., 1998; Hixson et al., 1999). In order to determine whether mutations 
within the melanocortin peptides might predispose to obesity, we screened the coding 
regions of the POMC gene for mutations in 538 UK Caucasian subjects with severe 
early-onset obesity in the absence of obvious glucocorticoid deficiency.  
Methods 
Cohorts and Human Genetic Studies 
538 UK Caucasian subjects with severe early-onset obesity were screened using a 
combination of direct nucleotide sequencing and denaturing high-performance liquid 
chromatography (Transgenomic WAVE DNA fragment analysis). Subjects were 
recruited as part of the Genetics of Obesity Study (GOOS) cohort (O'Rahilly et al., 2003), 
and mutations in leptin, leptin receptor, and MC4R genes had been excluded by direct 
nucleotide sequencing. These 538 subjects were selected from more than 960 subjects 
initially screened based on ethnicity, such that only Caucasian subjects were used for this 
study. The mean BMI SDS of this group was 3.8 ± 0.9, mean age of onset < 5 years. BMI 
SDS was calculated using age- and gender-specific UK population data (Cole et al., 
1995). All studies were approved by the local ethics committee and were conducted in 
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accordance with Declaration of Helsinki principles. Each subject, or the parent in the case 
of children below 16 years of age, provided written informed consent.  Subjects with 
mutations of the POMC gene and their relatives were invited to the Wellcome Trust 
Clinical Research Facility at the Addenbrooke’s Hospital, Cambridge, United Kingdom, 
for further assessment.  
 
Three hundred randomly selected non-obese adult controls from the MRC Ely 
Study (Wareham et al., 2000) were screened using the same techniques to compare the 
allelic frequency and facilitate interpretation of the potential pathogenicity of the 
mutations found.  
Detection of mutations and genotyping   
Genomic DNA was isolated from whole blood lymphocytes.  The coding region of 
POMC gene, located in part of exon 2 and in exon 3, is screened by a combination of 
denaturing high-performance liquid chromatography (DHPLC) (Transgenomic WAVETM 
DNA fragment analysis system, Nebraska, USA) and direct sequencing.  Exon 2 is 
analysed by DHPLC following PCR (c.-164T to c.132+55G).  Exon 3 is analysed as three 
overlapping segments, where the first segment (5’ end to c.348G) is analysed by direct 
sequencing following amplification of the whole exon.  The middle (c.303G to c.685G) 
and third (c.535G to c.804+56T) (3’ end) segments of exon 3 were amplified by PCR and 
analysed by DHPLC.  The first segment was analysed by direct sequencing in view of the 
increased number of genetic variants in that region as reported in the literature. All 
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abnormal waveforms detected by DHPLC are re-analysed by PCR and direct sequencing 
to identify the genetic variants responsible.  Sequencing was performed using BigDye® 
v3.1 Terminator Cycle Sequencing Kit (Applied Biosystems, Carlifornia, USA) and 
analysed on the ABI 3100 Avant Genetic Analyser.  Sequences were assembled and 
examined using Sequencher software (Gene Codes, Ann Arbor, Michigan, USA).  Prior to 
the mutation screening proper, a preliminary screen of POMC gene of 100 DNA samples 
by direct sequencing found several variants, and the samples with these variants were 
subjected to our DHPLC method which yielded abnormal waveforms, and this support 
our mutation detection method.   
 
The PCR was performed using BioTaq (Bioline, London, United Kingdom), or 
AmpliTaq Gold (Applied Biosystems, Carlifornia, USA) with proofreading Pfu DNA 
polymerase (Promega) for PCR products for DHPLC (ratio 9:1).  Primers for exon 2 PCR: 
forward 5’-TTC TCA GCA TTG CTG CTG TCC-3’, reverse 5’-CCA GCT CCA GTC 
CCA TCT AAT-3’; PCR conditions: 1 mM MgCl2 (final concentration), 950C 10 min 
(hot start), followed by 35 cycles of 95oC x 30 s, 63.9oC x 1 min, 72oC x 30 s,  then 
followed by 72oC x 7 min final extension.  Primers for exon 3 PCR: forward 5’-CCT 
AGG CGC AGT GAC GGG CG-3’, reverse 5’-AGC AGG GCA GGG GAG AGC AAG-
3’; PCR conditions: 1 mM MgCl2, 950C 2 min, followed by 35 cycles of 95oC x 30 s, 
69.5oC x 1 min, 72oC x 1 min,  then followed by 72oC x 7 min final extension.  Primers 
for amplification of middle segment of exon 3: forward 5’-GCA GAA GCG CGA GGA 
CGT CTC-3’, reverse 5’-CCC AGC GGA AGT GCT CCA TCC-3’; PCR conditions: 1.5 
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mM MgCl2, 950C 10 min (hot start), followed by 35 cycles of 95oC x 30 s, 66.8oC x 1 
min, 72oC x 30 s, then followed by 72oC x 7 min final extension.  Primers for 
amplification of third segment of exon 3: forward 5’-GAG CTG ACT GGC CAG CGA 
CT-3’, reverse 5’-AGG GGC TTT GGG GTC GAC CTC-3’; PCR conditions: 1 mM 
MgCl2 (final concentration), 950C 10 min (hot start), followed by 35 cycles of 95oC x 30 
s, 63.4oC x 1 min, 72oC x 30 s, then followed by 72oC x 7 min final extension.  
Sequencing primers for exon 2: forward 5’-TGC TGC TGT CCT TAA AAT GCC-3’, 
reverse 5’-CCA GCT CCA GTC CCA TCT AAT-3’.  Forward sequencing primers for 
exon 3: 5’-AGG CGC AGT GAC GGG CGC GGC-3’, 5’-TCT CAG CGG GCG AAG 
ACT GC-3’, 5’-GAG CTG ACT GGC CAG CGA CT-3’.  Reverse sequencing primers 
for exon 3: 5’-AGT AGG AGC GCT TGC CCT CG-3’, 5’-CTG TAG GGG CCC TCG 
TCC TTC-3’, 5’-TTT GGG GTC GAC CTC CTG GG-3’.      
 
Denaturing high-performance liquid chromatography (DHPLC) analysis: 
Unpurified PCR products at 3:1 ratio with a wild-type reference before subjected to a 3 
min, 95 °C denaturing step followed by gradual reannealing from 95–65 °C over 30 min. 
5 μL of each mixture was loaded onto a DNASep column (Transgenomic, Omaha, Neb., 
USA) and the amplicons were eluted in 0.1 M triethylammonium acetate, pH 7, with a 
linear acetonitrile gradient at a flow rate of 0.9 ml/min2. Heteroduplex mismatches were 
recognized by the appearance of aberrant patterns in the elution profiles under 
appropriate temperature conditions, which were calculated by the WAVEMaker software 
  55
ver 3.4.4 of the Wave Nucleic Acid Fragment Analysis system HSM device 
(Transgenomic, Omaha, USA). 
 
Genotyping of the Tyr221Cys variant was performed in 4849 subjects from a UK 
Caucasian population-based cohort, the EPIC-Norfolk study (mean [SD] BMI 25.9 [3.7] 
kg/m2, age 57 [9.3] years) (Khaw et al., 2001). This was performed by our collaborators 
Dr Matthew Sims, Dr Manj Sandhu, and Dr Nicholas J Wareham from the MRC 
Epidemiology Unit, Cambridge, United Kingdom. 4846 of the control subjects (55% 
women) did not carry this POMC variant, and only 3 (all women) were heterozygous for 
this variant. These subjects were screened using a custom-made assay based on TaqMan 
chemistry (Applied Biosystems, Warrington, United Kingdom). The assay conditions 
were 95 oC for 10 mins, then 40 cycles of 92 oC for 15sec, and 54 oC for 1 min on 10ng 
primer-extension preamplified DNA.  The probe and primer information: Probe 1 Tm 
65.4 oC, GC 76.9%, Length 13 bp, VIC fluorescence, AGGGCCCCTgCAG; Probe 2 
Tm 66 oC, GC 71.4%, Length 14 bp, FAM fluorescence, AGGGCCCCTaCAGG. Left 
primer CCGACCTGGAGCACAGC, right primer TTCTCGGAGGTCATGAAACC. 
 
Genotyping of the Tyr221Cys variant was also performed in two groups of French 
obese subjects: 597 morbidly obese adults (BMI 47.5 ±7.53), 535 obese children (BMI 
sds = 4.37 ± 1.31) and also in 723 lean controls (BMI 23.29 ± 2.74). These subjects were 
genotyped using a FRET (Fluorescence Resonance Energy Transfer) based assay using 
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the LightTyper technology (Roche, Meylan, France and Mannheim, Germany) as 
previously reported (Meyre et al., 2005). Probes for LightTyper were synthesized by TIB 
Molbiol Syntheselabor Germany. This was performed by Dr Vincent Vatin, Dr David 
Meyre, and Prof Philippe Froguel from the Institute of Biology, Pasteur Institute, Lille, 
France and Section of Genomic Medicine and Genome Centre, Imperial College London, 
UK.  
 
Nuclear Magnetic Resonance (NMR) studies 
The NMR studies were performed by Darren A. Thompson, Michael E. Madonna, and 
Glenn L. Millhauser from the Department of Chemistry and Biochemistry, University of 
California, Santa Cruz, California. Two-dimensional 1H NMR (2D-NOESY and 2D-
TOCSY) performed on peptides corresponding to the β-MSH segment of POMC was 
used to assign chemical shifts in both wild-type and a mutant with a Tyr221Ser mutation. 
Ser was used instead of Cys since, at NMR concentrations, free -SH groups tend to form 
disulfides. For flexible peptides, a negative CSI indicates a turn or helical structure and a 
positive CSI indicates the presence of extended, β sheet conformers (Mielke and 
Krishnan, 2004; Wishart et al., 1992). 
Receptor activation studies 
The mutant [Gln6] α-MSH and [Cys5] ß-MSH peptides were synthesized (Bachem, St 
Helens, Merseyside, UK) and determined to be >96% pure by HPLC.  Mass spectrometry 
confirmed the composition of the peptides.  Wild-type human α-MSH (Bachem) and β-
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MSH (Bachem) were >98% pure by HPLC.   Wild-type and mutant α-MSHs were 
supplied as trifluoroacetate salts and N-acetylated.  Appropriate dilutions of wild-type α-
MSH and β-MSH and mutant peptides were prepared in their respective diluents as 
recommended by manufacturer.  Wild type α-MSH and β-MSH were dissolved in 0.05% 
acetic acid, mutant [Gln6] α-MSH in water, and mutant [Cys5] ß-MSH in 0.1% 
trifluoroacetic acid to maintain low pH and reduce dimerisation risk.  Wild-type MC4R 
was amplified directly from control DNA using primers MC4Rforward (5'-
AATAACTGAGACGACTCCCTGAC-3') and MC4RrevEco (5'-
CGCTTAAGTTAATATCTGCTAGACAAGTCAC-3'). MC4Rforward flanks an 
endogenous EcoRI site, whereas MC4RrevEco contains a terminal EcoRI restriction site, 
thus facilitating cloning of the PCR products into the mammalian expression vector 
pcDNA3 (Invitrogen Corp., San Diego, California, USA). PCR was performed using 
Expand DNA polymerase (Roche Diagnostics Corp., Indianapolis, Indiana, USA), 
according to manufacturer’s protocols. Cloned product was then sequenced.   
 
HEK293 cells were transiently transfected with wildtype MC4R and cotransfected 
with a cAMP-dependent luciferase reporter construct. cAMP/Luciferase reporter assays 
were performed as described previously (Yeo et al., 2003). HEK293 cells were 
maintained in DMEM (Life Technologies, Rockville, Maryland, USA) supplemented 
with 10% FBS, 100 U/mL penicillin, 100 µg/mL streptomycin, and 250 ng/mL 
Fungizone (Life Technologies).  Cells were incubated at 37°C in humidified air 
containing 5% CO2, and transfections were carried out using Fugene reagent (Roche 
  58
Diagnostics Corp) according to manufacturer’s protocols. Cells were generally at 70–80% 
confluence on the day of transfection. The cAMP responsive luciferase construct (pLUC) 
was used here as described previously (Persani et al., 1993): 300 ng of wild-type MC4R 
expression vector was transfected with 60 ng pLUC reporter construct and 20 ng of 
internal control plasmid, pRL-CMV (Promega Corp., Madison, Wisconsin, USA), which 
constitutively expresses Renilla luciferase. After transfection, cells were serum starved for 
8 hours. Varying concentrations of wild-type and mutant MSH peptides were then added 
to the cells and allowed to incubate for 16 hours. The cells were lysed, and the two 
different luciferases were sequentially activated and quenched using the Dual-Luciferase 
Reporter Assay System (Promega) and the resulting luminescence detected using an 
AutoLumat LB953 luminometer (EG&G Berthold, Baqd Wildbad, Germany) according 
to manufacturers’ protocols.  Mock transfection of HEK293 cells using pCDNA3 vectors 
without MC4R inserts were performed and used as controls. 
Competitive binding studies 
Whole HEK293 cells stably expressing wild-type MC4R were exposed to tracer amounts 
of [125I]NDP-MSH, and the ability of increasing concentrations of β-MSH or [Cys5] β-
MSH to inhibit radioligand binding was measured as described previously (Yeo et al., 
2003). All wild-type and mutant peptides were obtained from Bachem as described 
previously. MC4R inserts with sticky EcoRI ends were cut from the pCDNA3/MC4R 
construct described above, and cloned into pIRESpuro3 vector (BD Bioscience Clontech, 
NJ, USA), which confer resistance to puromycin.  Transfection was carried out using 
Fugene reagent (Roche Diagnostics Corp) according to manufacturer’s protocols, and the 
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transfected HEK293 cells were then selected with puromycin at 3 mcg/ml of medium 
over four weeks.  Stable expression of MC4R by the cells were confirmed with reverse 
transcription PCR, and a dose response in cAMP production to increasing concentration 
of stimulatory wild-type α-MSH as described above.  Cells were harvested washed once 
in binding buffer [minimal essential salts, 25 mM HEPES pH 7.0 (Invitrogen Life 
technologies), 0.2% BSA] and distributed in 96-well plates. Appropriate dilutions of α-
MSH, β-MSH, and mutant peptides were prepared in binding buffer.  Cells were 
incubated at room temperature for 2 h with 0.05 ml of binding buffer containing 0.0037 
Mbq of [1251]NDP-MSH ([Nle4, D-Phe7]-α-melanocyte stimulating hormone (Amersham, 
UK) and the appropriate concentration of study peptide.  Non-specific binding was 
determined in the presence of 10 µM α -MSH.  The cells were then washed once with 
0.1 ml ice cold binding buffer, once with 0.1 ml ice cold PBS, and resuspended in 0.1 ml 
Microscint 20 (Perkin Elmer / Packard).  Radioactivity was counted using a Packard 
Topcount Microplate Scintillation Counter according to the manufacturer's instructions.  
Physiological studies 
Measurements of food intake and body composition were undertaken after appropriate 
informed consent and using protocols previously described (Farooqi et al., 2003). Height 
was measured to the nearest 0.5 cm using a portable free-standing stadiometer (Leicester 
Height Measure, London, United Kingdom). Weight was measured in the fasting state on 
a digital electronic balance accurate to the nearest 100 g (Fereday & Sons 824/890, 
London, United Kingdom).  Body composition was measured using whole-body dual-
energy x-ray absorptiometry (DXA) to determine bone mineralization, total lean mass, 
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and total fat mass (DPX software; Lunar Corp., Madison, Wisconsin, USA). A 
semiquantitative assessment of ingestive behavior was undertaken in children under the 
age of 18 years. An ad libitum meal of fixed size and content (18 MJ) was provided at 
breakfast after an overnight fast. The contents were covertly weighed before and after 
consumption and total energy intake and nutrient composition calculated using standard 
tables (Farooqi et al., 2003). In addition, energy intake was expressed per kilogram of 
lean body weight as a means of comparing intake between subjects of different age and 
body size.  
Data analysis   
Graph fit curves and EC50/IC50 were obtained and performed using GraphPad Prism 4 for 
Windows (ver 4.02 GraphPad software, San Diego, California, USA), and curves were 
fitted using the logistical equation. For transient tranfection studies, data is expressed as 
fold induction of luciferase activity, and each point represents the mean and standard 
error range of 10 independent experiments performed in quadruplicate.  For ligand 
binding studies, data is expressed as a percentage of the maximum counts of [125I]NDP-
MSH binding to wild-type MC4R for each respective ligand. Each point represents the 
mean and standard error range of four independent experiments in triplicates.  
Results 
Identification of missense mutations in POMC 
We identified a number of sequence variants in POMC in severely obese children (Table 
3-1). In addition to a number of synonymous SNPs and a common 9 bp insertion that has 
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been reported previously (Challis et al., 2002; Echwald et al., 1999; Miraglia del Giudice 
et al., 2001), we identified seven rare nonsynonymous SNPs. Three of these missense 
mutations directly affect regions of the POMC gene that encode melanocortin peptides 
(Figure 3-1). Arg236Gly was identified in three patients but also two controls. This 
mutation disrupts a di-basic cleavage site between β-MSH and β-endorphin (β-end), 
resulting in a β-MSH/ β-endorphin fusion protein that binds to MC4R but has reduced 
ability to activate the receptor (Challis et al., 2002). Previous studies showed that this 
mutation was present in both obese subjects and controls but not highly prevalent, and 
while it is not a highly penetrant cause of inherited obesity, this mutation may increase 
the risk of obesity (Challis et al., 2002; Echwald et al., 1999). Novel heterozygous 
missense mutations were found in the POMC region which codes for β-MSH (Tyr221Cys, 
five subjects) and α-MSH (His143Gln, one subject). Other mutations were rare and/or 
occurred in regions of the POMC pro-peptide of uncertain function. Our further studies 
concentrated on the α- and β-MSH variants.  
 
The Novel mutation Tyr221Cys is linked with obesity or overweight status 
A novel heterozygous missense mutation Tyr221Cys in β-MSH coding region was found 
in five unrelated UK Caucasian probands (Table 3-1) (figure 3-2). This variant was also 
found in 1/300 non-obese UK Caucasian adults. To establish the frequency of this allele 
in an unselected UK Caucasian population, we genotyped a random subset of 5000 
subjects recruited to the EPIC-Norfolk study. 4,852 subjects were successfully genotyped, 
and we identified 3 heterozygotes, all of whom were non-obese. Thus, Tyr221Cys is 
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found at significantly higher frequency in a population of UK Caucasians subjects with 
early-onset obesity than in unselected UK Caucasian controls (5/538 versus 4/5152, Chi-
Square 22.4, p < 0.001). i.e. Tyr221Cys in β-MSH is more common in obese subjects 
than in controls. The Tyr221Cys variant was not found in 1132 obese French Caucasian 
subjects (597 morbidly obese adults [BMI 47.5 ± 7.53] and 535 obese children [BMI sds 
= 4.37 ± 1.31]), nor in 723 lean French Caucasian subjects (BMI 23.29 ± 2.74). These 
observations suggest that Tyr221Cys is likely to be a rare variant in Caucasian 
populations.  
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Table 3-1. Identification of variants in POMC. Synonymous and nonsynonymous 
variants in severely obese children and controls. 
POMC variants Obese children (n = 538) Controls (n = 300) 
Nonsynonymous SNPs & insertion 
Leu37Phe 1 0 
9 bp insertion (c.297-298insAGCAGCGGC) 51 (9.48%) 28 (9.33%) 
Pro132Ala 1 0 
His143Gln 1 1 (0.33%) 
Ala195Thr 1 0 
Glu214Gly 8 (1.49%) 2 (0.67%) 
Tyr221Cys 5 (0.93%) 1 (0.33%) 
Arg236Gly 3 (0.56%) 2 (0.67%) 
Synonymous SNPs 
Cys6Cys 5 0 
Ser94Ser 4 0 
Ala195Ala 4 (0.74%) 1 (0.33%) 
Leu116Leu 8 (1.49%) 7 (2.33%) 
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Figure 3-1. Structure of POMC and location of rare missense mutations.  























Figure 3-2. A heterozygous missense mutation due to a single base substitution from A 
to G (highlighted and affected codon boxed), resulting in change of the 5th residue of β-













To examine whether this variant cosegregates with obesity/overweight in families, first-
degree relatives were contacted, and those who agreed were examined and genotyped 
(Figure 3-3). Thirteen relatives were heterozygotes for Tyr221Cys, 11 of which were 
obese, two overweight, and none lean. Five relatives were wild-type, three of which were 
obese and two lean. Thus, in total, in these families, 0/20 Tyr221Cys carriers and 2/5 
wild-type subjects were lean.  
Tyr221Cys β-MSH mutation alters three-dimensional structure of β-MSH 
Tyr221 is a highly conserved residue, being present in the β-MSH sequence of species 
from teleost fish through to mammals (accession numbers: Zebrafish NP_852103, 
Chicken BAA34366, Mouse P01193, Rat AAA41903, Human P01189) (figure 3-4). A 
tyrosine is also present in the equivalent position in all melanocortins from all 
mammalian species (figure 3-5), i.e. located 4 residues upstream of the core binding 
motif His-Phe-Arg-Trp (HFRW), which is essential for binding to the melanocortin 
receptors. To determine whether Tyr221 is necessary for the normal three-dimensional 
structure of β-MSH, our collaborator undertook NMR studies of wild-type and a mutant 
peptide analog replacing Tyr221 with Serine (to avoid intermolecular disulfide formation 
common with Cys-containing peptides). Chemical Shift Index (CSI) values were used to 
probe average structural properties (Mielke and Krishnan, 2004; Wishart et al., 1992). 
Compared to wild-type β-MSH, the mutation resulted in a significantly reduced helical 
turn propensity for two of the three residues between the mutation site and the His-Phe-
Arg-Trp receptor binding motif (Figure 3-6).  
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Figure 3-3. Cosegregation of Tyr221Cys β-MSH mutation with obesity (black symbols) 
and overweight (gray symbols) in families. Genotype (N = wild-type allele, M = mutant 
allele) and BMI sds is denoted. In adults, overweight defined as BMI 25–30 kg/m2, 
obesity as BMI > 30 kg/m2. In children, overweight defined as >91st and obesity as >99th 
percentile for age-adjusted BMI. Arrows indicate the proband of each family.  
NM          NN                        NM               NM      NN      NM      
1.6           -0.3                       2.3                4.3                2.6      1.1   
NM                   NM       NN          NN        NM        NM     NM          NM              NM      














Figure 3-4. Sequence alignment of β-MSH peptides of different species. The tyrosine 
residue (underlined and in bold) is highly conserved, and invariably located 4 residues 





















Figure 3-5. Tyrosine residue (underlined and in bold)) is present and located 4 amino 
acid residues upstream of the core binding motif His-Phe-Arg-Trp (HFRW) (in bold) of 
various POMC derived peptides, namely the adrenocorticotropic hormone (ACTH), and 








Figure 3-6. Comparison of the Chemical Shift Index (CSI = experimental chemical 
shift—consensus random coil chemical shift) values between wild-type and mutant β-
MSH. Throughout the segment Arg-Met-Glu-His-Phe-Arg-Trp, the CSIs for both 
peptides were indicating the presence of turns (values ranging from −0.01 to −0.24). For 
the receptor binding motif, His-Phe-Arg-Trp, both wild-type and mutant peptides gave 
approximately identical values. However, for the Arg-Met residues following the 
mutation, but preceding the receptor binding motif, the wild-type sequence showed a 




Arg     Met           Glu          His           Phe          Arg           Trp 
Core receptor binding motif 
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Tyr221Cys β-MSH mutation alters [Cys5] β-MSH signaling through MC4R 
When compared to wild-type β-MSH, a synthetic peptide incorporating the 
Tyr221Cys mutation showed reduced binding to MC4R stably expressed in HEK293 
cells (Figure 3-7) (IC50 of mutant β-MSH = 797.1 ± 261.0 nM compared to 67.2 ± 43.0 
nM of wt β-MSH, p = 0.006).  
Consistent with these findings, the addition of wild-type β-MSH led to a dose-
dependent increase in cAMP accumulation in HEK293 cells transiently expressing 
MC4R, while Tyr221Cys generated significantly less cAMP (Figure 3-8) (EC50 mutant β-
MSH = 1.95 nM compared to 0.1 nM of wt β-MSH, p = 0.04).  
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Figure 3-7. [Cys5] β-MSH binds to MC4R with lower affinity than β-MSH. Whole 
HEK293 cells stably expressing wild-type MC4R were exposed to tracer amounts of 
[125I]NDP-MSH, and the ability of increasing concentrations of β-MSH or [Cys5] β-MSH 
to inhibit radio-ligand binding was measured as described previously. Data are expressed 
as a percentage of maximum counts of [125I]NDP-MSH binding to MC4R. Each point 
represents the mean (±SEM) of four independent experiments in triplicate. 
Competitive Binding Study






































Figure 3-8. [Cys5] β-MSH has a markedly reduced ability to stimulate production of 
cAMP. Graphs indicate responses of wild-type, mutant, and control constructs to a 
logarithmic increase in β-MSH concentration. cAMP/Luciferase reporter assays were 
performed as described previously. Open symbols denote mock transfected controls. 
Each point represents the mean (±SEM) of eight independent experiments performed in 
quadruplicate.  
Transient Transfection Study: WT vs. Mut β-MSH





























Clinical phenotype of subjects with Tyr221Cys mutation in β-MSH 
To establish whether obese children carrying the β-MSH mutation were hyperphagic, we 
admitted six children heterozygous for Tyr221Cys β-MSH (five probands and one 
relative) to the Addenbrooke's Hospital Clinical Research Facility. The six children 
underwent an ad libitum test breakfast. Ad libitum caloric intake, expressed per kg lean 
mass, was markedly increased compared to normal weight control children (Figure 3-9A) 
and similar to that seen in subjects heterozygous for MC4R mutations (Farooqi et al., 
2003). Basal metabolic rate of affected subjects was not significantly different from that 
predicted using age- and gender-specific equations (data not shown). In order to 
determine whether obese children carrying the β-MSH mutation had other phenotypic 
similarities to children with known defects in MC4R signaling, we assessed body 
composition using standard procedures (Farooqi et al., 2003). The children with the β-
MSH mutation more closely resembled MC4R heterozygotes than equivalently obese 
children (with normal MC4R and POMC sequence) in terms of accelerated linear growth 
and increased fat-free mass (Figures 3-9B and 3-9C). 
  75
Figure 3-9. Phenotypes of subjects with Tyr221Cys mutation  
A) Food intake at an 18MJ ad libitum test meal compared to normal weight controls. 
Food intake is expressed per kg lean body mass measured by dual energy X-ray 
absorptiometry (DXA) to allow comparison between subjects of different ages (Farooqi 
et al., 2003) ***p < 0.001.  
B) Height SDS in children with the Tyr221Cys mutation in β-MSH compared to 
heterozygotes for MC4R mutations and controls of comparable age and degree of obesity. 
**p < 0.01  
C) Fat-free mass (FFM) measured by DXA in children with the Tyr221Cys mutation in 
β-MSH compared to heterozygotes for MC4R mutations and controls of comparable age 




A novel missense mutation His143Gln in α-MSH 
As described above, one UK Caucasian proband was found to have a missense POMC 
mutation (His143Gln) located in the region coding for α-MSH (Figures 3-1 and 3-10A). 
However, this was also present in one of the 300 UK Caucasian controls. The grandfather 
of the proband carried the mutation and was obese, but the transmitting parent was lean 
(Figure 3-10B). 
The mutation replaces a highly conserved residue within the classical His-Phe-
Arg-Trp receptor binding motif of the melanocortins and would be expected to impair 
function. Consistent with this, a synthetic mutant peptide [Gln6] α-MSH has marked 
reduced affinity for the MC4 receptor (Figure 3-11) (IC50 of mutant α-MSH = 1624 ± 624 
nM compared to 15.2 ± 14.0 nM of wt α-MSH, p < 0.0001). The His143Gln mutant α-
MSH also had reduced ability to stimulate cAMP generation from MC4R (Figure 3-12) 
with a reduced maximal response, although the EC50 was not significantly different from 
wild-type (EC50 mutant α-MSH = 3.8 nM compared to 2.2 nM of wt α-MSH, p = ns). 
Thus, while heterozygous disruption of α-MSH function may play a contributory role in 
the obesity of the proband, the presence of this mutation in a lean transmitting family 
member implies that it is insufficient, in itself, to fully explain the obese phenotype.  
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Figure 3-10A. A heterozygous missense mutation His143Gln due to a single base 
substitution from C to G (highlighted, and affected codon boxed), resulting in change of 
the histidine residue of highly conserved core binding motif His-Phe-Arg-Trp (HFRW) to 








Figure 3-10B. Cosegregation of His143Gln α-MSH mutation with obesity (black 














Figure 3-11. [Gln6] α-MSH binds to MC4R with lower affinity than α-MSH (methods as 
in Figure 3-7). Data is expressed as a percentage of maximum counts of [125I]NDP-MSH 
binding to MC4R. Each point represents the mean (±SEM) of four independent 
experiments in triplicate.  
Competitive Binding Study





































Figure 3-12. [Gln6] α-MSH has a markedly reduced ability to stimulate production of 
cAMP (methods as in figure 1E). Open symbols denote mock-transfected controls. Each 
point represents the mean (±SEM) of eight independent experiments performed in 
quadruplicate.  
Transient transfection study: WT vs. Mutant α-MSH

































Tyr221Cys mutation in β-MSH is associated with human early-onset obesity 
These studies provide compelling evidence that β-MSH is likely to be a physiologically 
relevant, endogenous ligand for the MC4R in humans. Firstly, the Tyr221Cys variant is 
enriched in a population of UK Caucasian subjects with early-onset obesity compared to 
its background prevalence in the UK population. The overrepresentation of this mutation 
in obese subjects is supported by an independent study in a German population 
(Biebermann et al., 2006). The fact that we did not find this variant at all in a large 
French population suggests that this variant may have arisen relatively recently in 
European ancestry.  
Further support for the importance of β-MSH in energy homeostasis is provided 
by a previous observation of an association of a cleavage site mutation Arg236Gly 
affecting β-MSH with obesity although, in contrast with Tyr221Cys, that mutation 
resulted in the production of a β-MSH/β-endorphin fusion peptide with reduced ability to 
activate MC4R but normal binding affinity, and thus has the potential to interfere with 
signaling at the MC4R in a dominant-negative manner (Challis et al., 2002). It is unlikely 
that Tyr221Cys would result in a dominant-negative interference with wild-type β-MSH, 
so we hypothesize that this mutation simply reduces the amount of β-MSH tone at the 
MC4R and that this in itself is sufficient to predispose to obesity. The plausibility of such 
a model is supported by the increased prevalence of obesity and overweight in carriers of 
POMC null mutations ((Farooqi et al., 2006; Krude et al., 2003).  
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It is important to note that the Tyr221Cys mutation is unlikely to be a highly 
penetrant cause of monogenic obesity, but that apparent enrichment in obese populations 
is likely to occur because it is an allele that increases the risk of obesity. Our conclusion 
is supported by the fact that human and murine heterozygotes for null mutations in 
POMC show a propensity to increased adiposity but are not all frankly obese, and some 
carriers of the Tyr221Cys β-MSH mutation are not obese.  
Both α-MSH and β-MSH influence melanocortinergic tone in humans 
The vast majority of the literature concerning the POMC system and energy homeostasis 
focuses on the possible role of α- rather than β-MSH as the endogenous ligand (Coll et al., 
2004; Cone, 2005), as the N-terminal cleavage site necessary for the generation of β-
MSH is absent in rodents. In contrast, β-MSH has been established to be present in the 
human hypothalamus as a normal maturation product of POMC (Bertagna et al., 1986). 
We also found a rare missense mutation in α-MSH in a single proband, which had a 
major deleterious effect on its function. However, this variant was found in one lean 
family member and one lean unrelated control. While it is possible that this variant is 
contributing to the obesity of the proband, it is notable that our human genetic studies 
provide more compelling evidence for a specific role for β-MSH than α-MSH in the 
control of human energy balance. Finally, the similarities in clinical phenotype between 
obese children carrying the Tyr221Cys β-MSH mutation and those with MC4R mutations 
(Farooqi et al., 2003) suggest that both mutations are affecting shared physiological 
pathways. In conclusion, β-MSH is likely to be an important and physiologically relevant 
endogenous ligand for the human MC4R. These findings illustrate how studies of human 
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genetics can provide insights into the important physiological roles of particular species-
restricted peptides that are not obtainable through the study of rodent models.  
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Novel mutations of the pro-opiomelanocortin (POMC) gene which affect POMC 
sorting to regulated secretory pathway 
 
Summary 
The functional loss of both alleles of the human pro-opiomelanocortin (POMC) gene 
leads to hypoadrenalism, red hair, fair skin, and early-onset obesity due to impaired 
synthesis POMC-derived peptides, and even heterozygous POMC mutations which affect 
the production or functional structure of melanocortin peptides can predispose to human 
obesity. In order to examine whether more subtle genetic variants in POMC might 
contribute to early-onset obesity, the coding region of the gene was sequenced in 960 
subjects with a history of severe obesity from childhood (GOOS cohort). Two 
heterozygous missense mutations, Cys28Phe and Leu37Phe, were found in a Turkish 
subject and a Caucasian subject respectively, and were absent in 100 Turkish and 300 UK 
Caucasian controls. Both mutations result in substitution of highly conserved residues in 
a region of the N-terminus (N-terminal peptide) that is considered to be the sorting signal 
motif of POMC, involved in its sorting to the regulated secretory pathway. This 
Cys28Phe variant co-segregated with obesity in the family, but not as well for the 
Leu37Phe. Metabolic labeling with immunoprecipitation, Western blot studies, and 
immunoassay analysis of lysates were performed using β-TC3 cells transiently 
transfected with POMC cDNA and co-transfected with prohormone convertase 2 and its 
chaperone, 7B2. Metabolic labeling studies indicate that while the mutations do not 
reduce intracellular levels of POMC, both mutations impair the ability of POMC to be 
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processed to generate bioactive products (Cys28Phe more so than Leu37Phe). Studies of 
the secretion of POMC products suggest, particularly with Cys28Phe, that the impaired 
propeptide processing of these mutations results from a mistargeting of mutant POMC to 
the constitutive rather than the regulated secretory pathway. No dominant negative effect 
was detected. This is consistent with previous reports that inactivating heterozygous 
POMC mutations can predispose to human obesity.  These mutations in patients with 
early onset obesity represent a novel molecular mechanism of POMC deficiency whereby 
naturally occurring mutations in its N-terminal sequence impair the ability of POMC to 




As discussed in the previous chapters, homozygous nonsense or missense mutations in 
POMC are associated with hyperphagia, early onset obesity, hypopigmentation and 
isolated ACTH deficiency, and loss of one copy of POMC is sufficient to predispose to 
obesity, likely due to haploinsufficiency (Farooqi et al., 2006; Krude et al., 2003). A 
variety of heterozygous missense POMC mutations are found more commonly in obese 
children (Challis et al., 2002; Lee et al., 2006).  
 
POMC (accession no. NP_000930) is a pro-peptide synthesized on the rough 
endoplasmic reticulum, and then transported to the trans-Golgi network (TGN) where it 
is packaged into immature secretory granules of the regulated secretory pathway (RSP). 
The POMC-derived peptides are secreted via both constitutive and regulated secretory 
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pathways. Within these granules, POMC is cleaved by endoproteases to yield the active 
peptides, which are stored in mature (dense core) granules to be released upon 
stimulation (Pritchard and White, 2007). Thus POMC undergoes tissue-specific post-
translational processing during sorting as it transit through the golgi network and 
secretory vesicles, the products of which include ACTH and β-lipotropin (β-LPH) after 
cleavage by prohormone convertase 1 (PC1) localized to the TGN as well as secretory 
granules (Christie et al., 1991; Hornby et al., 1993; Kirchmair et al., 1992), and then by 
prohormone convertase 2 (PC2) which acts in a post-Golgi compartment or in secretory 
granules (Benjannet et al., 1993; Bennett et al., 1992; Johanning et al., 1996; Rouille et 
al., 1995; Zhou et al., 1993; Zhou et al., 1995) to further yield the melanocortin peptides 
α, β, and γ-MSH and β-endorphin (β-end) (figure 4-1) (Pritchard et al., 2002; Raffin-
Sanson et al., 2003; Seidah and Chretien, 1999). There is evidence to suggest that the N-
terminal peptide (NT) of POMC carries a sorting signal motif which directs POMC to the 
regulated secretory pathway (Cool et al., 1995; Cool et al., 1997). To date, no naturally 
occurring variants in this region of the human POMC gene have been described.  
 
In a mutation screen of subjects with early onset obesity from the GOOS cohort, 
two heterozygous missense mutations located in the NT region of POMC were found in a 
Caucasian proband and Turkish proband.  Functional studies revealed that both mutations 
may interfere with sorting of POMC into the regulated pathway and result in reduced 
secretion of the melanocortin peptides.   
  87
Figure 4-1. POMC post-translation processing by PC1 (black arrow) and PC2 (clear 
arrow) at dibasic cleavage sites (solid line). Tissue specific expression results in a 
different range of peptides produced in the anterior pituitary (grey) compared with the 
hypothalamus (black) (figure modified from Coll, A.P., Farooqi, I.S., Challis, B.G., Yeo, 
G.S., and O'Rahilly, S. [2004]. Proopiomelanocortin and energy balance: insights from 
human and murine genetics. J Clin Endocrinol Metab 89, 2557-2562)  
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Methods 
Subjects and Human Genetic Studies 
More than 960 DNA samples from the GOOS cohort were screened for POMC mutations 
(in the coding region) using a combination of direct sequencing and dHPLC as described 
in the previous chapter (Lee et al., 2006). DNA and phenotypic information was obtained 
from family members of the probands with N-terminal peptide missense mutations and 
the genotype of relatives was ascertained by direct sequencing. The prevalence of each 
mutation in an appropriate ethnically matched control group (100 Turkish and 300 UK 
Caucasian controls) was determined using the same screening method for the GOOS 
cohort. Body mass index standard deviation scores were calculated using UK reference 
data (Cole et al., 1995). 
 
Construction of POMC Wildtype, Cys28Phe, and Leu37Phe expression vectors  
Construction of a human POMC expression vectors (in pcDNA3; Invitrogen Life 
Technologies) containing a c-Myc epitope tag near the carboxyterminus has been 
described previously (Challis et al., 2002). Briefly, the human POMC gene with a c-Myc 
epitope tag between codons 262 and 263 was subcloned into the eukaryotic expression 
vector pcDNA3 (Invitrogen).  The epitope tag precedes the KKGE sequence to avoid 
removal after cleavage at the KK sequence. This construct was used as template for 
mutagenesis to introduce the G to T (Cys28Phe) and C to T (Leu37Phe) mutations using 
a QuickChange Site-Directed Mutagenesis kit (Stratagene) according to the guidelines of 
the supplier. Mutations were confirmed by nucleotide sequencing. 
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Biochemical properties of POMC variants  
a) Metabolic labelling studies  
This experiment was performed by our collaborator Assoc Professor John WM Creemers 
from the University of Leuven Centre for Human Genetics, Leuven, Belgium. 5-6×105 
mouse insulinoma β-TC3 cells were transfected with a total of 2 μg expression vector 
and 6μl Lipofectamine 2000 (Invitrogen Life Technologies) and plated in 10 cm2 dishes. 
All experiments described below were performed in triplicate. Metabolic labeling was 
performed the next day for 1 h, using 200 μCi [35S]-methionine (Perkin Elmer; specific 
activity 1175 Ci/mmol) in 600 μl methionine-deficient RPMI-1640 medium (Sigma), and 
chased for 1 h in medium supplemented with excess (0.2 mM) unlabeled methionine. 
Cells were lysed in 1 ml lysis buffer (50 mM Tris/HCL pH 7.4, 150 mM NaCl, 1% Triton 
X-100) containing complete protease inhibitors (Roche Molecular Biochemicals). 
Lysates were pre-cleared with preformed complexes of protein G sepharose (GE 
Healthcare) and mouse pre-immune IgGs. Specific immunoprecipitation was performed 
with monoclonal antibody 9E10, directed against the c-Myc epitope. The 
immunoprecipitated proteins were size separated by SDS-PAGE (Criterion, Bio-Rad) and 
visualized by autoradiography. 
 
b) Studies of constitutive and regulated secretion  
Secretion studies of POMC variants was performed essentially as described previously 
(Creemers et al., 2006) with minor modifications (performed by Assoc Professor John 
WM Creemers from the University of Leuven Centre for Human Genetics). Briefly, cells 
were transfected as described above and then cultured for 16h in serum free medium, to 
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minimize the tonic release of POMC-derived peptides induced by serum factors. The next 
day, the cells were first incubated for 3 h with serum free medium (unstimulated fraction) 
and subsequently for 3 h with medium containing the secretagogues forskolin (10 μM 
[Sigma]) and IBMX (0.1 mM [Sigma]), which elevate the intracellular cyclic AMP 
concentration. After collection of this conditioned medium (stimulated fraction), the cells 
were lysed in laemmli sample buffer.  
 
Western Blot analysis (performed by Assoc Professor John WM Creemers from 
the University of Leuven Centre for Human Genetics): Culture medium from the 
experiment above was mixed with 25 μg/ml albumin before precipitation with 4 volumes 
of methanol at -20°C. Medium precipitates were dissolved in sample buffer and size 
separated by SDS-PAGE (Criterion, Bio-Rad). Western blotting was performed using 
monoclonal antibody 9E10 directed against the c-Myc epitope. 
 
POMC and α-MSH immunoassay (performed by Dr Rob L Oliver and Professor 
Anne White from the University of Manchester, Endocrine Sciences Research Group, 
Faculties of Life Sciences and Medical and Human Sciences): Culture media and cells 
from parallel experiments to those for western blotting were collected for POMC and α-
MSH analysis. Cells were lysed in 1 ml lysis buffer (50 mM Tris/HCL pH 7.4, 150 mM 
NaCl, 1% Triton X-100) containing complete protease inhibitors (Roche Molecular 
Biochemicals). α-MSH was measured by radio-immunoassay (Euro-diagnostica AB, 
Malmö, Sweden). POMC measurement with a two-antibody ELISA (Rousseau et al., 
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2007) based on the immunoradiometric assay previously described (Crosby et al., 1988) 
was planned, but not performed yet at the time of writing this chapter.  
 
Results 
Two novel mutations in the N-terminus of POMC 
We identified two novel heterozygous missense mutations in exon 2 of POMC (figure 4-
2A).  Cys28Phe (c.82G>T) was found in a 17 year old boy of Turkish origin with severe 
obesity and not in 100 control alleles of the same ethnic group. This mutation was also 
found in two other members of the family (figure 4-2B), both of whom were overweight 
(BMI 28 and 29 kg/m2 respectively). Leu37Phe (c.109C>T) was found in a 9 year old girl 
of UK Caucasian origin with severe obesity and not in 300 control alleles of the same 
ethnic group. The mutation was inherited from her mother who was overweight (BMI 27 
kg/m2) (figure 4-2B).  
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Figure 4-2A. Chromatograms for Proband 1 and 2 indicating heterozygosity for missense 
mutations Cys28Phe (c.82G>T) and Leu37Phe (c.109C>T) respectively (arrow). Affected 














Figure 4-2B. Co-segregation of Cys28Phe and Leu37Phe with overweight/obesity in 
family members. Filled symbols indicate probands; Genotypes are included where 
available - N denotes normal allele, M denotes mutant allele. Body mass index (BMI) 
standard deviation scores are indicated beneath genotype (Cole et al., 1995); BMI (kg/m2) 
is indicated in parentheses for subjects > 16yrs of age  
 
  94
Both residues are located in the N-terminal region of POMC (Figure 4-3) which 
has previously been implicated in the sorting of POMC to the regulated secretory 
pathway. Both Cys28 and Leu37 are highly conserved across multiple species (accession 
numbers: Zebrafish NP_852103, Chicken BAA34366, Mouse P01193, Rat AAA41903, 
Human NP_000930) (Figure 4-4). This region contains two disulfide bridges stabilizing 
an amphipathic hairpin loop structure between the second and third cysteine residues 
(figure 4-5) (Cool et al., 1995). The mutation Cys28Phe resulted in the loss of the outer 
disulphide bridge, while Leu37Phe led to the loss of the highly conserved Leu37 residue, 
part of the amphipathic motif comprising of four highly conserved hydrophobic and 




Figure 4-3. Structure of POMC and location of mutations. Cys28Phe and Leu37Phe are 
located in the N terminal region of POMC distant from previously reported missense 
mutations (arrows) associated with obesity. The signal peptide (1st – 26th residues) is 
necessary for the translocation of the nascent protein through the membrane of the rough 
endoplasmic reticulcum (RER), and is then rapidly cleaved.  The POMC protein is then 
engaged in the secretory pathway and ready for processing by the prohormone 
convertases (PC1 & PC2). 
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Figure 4-4. Sequence alignment shows that Cys28 and Leu37 residues are highly 
conserved residues, present in the POMC sequence of species from fish through to 
mammals (figure modified from Cool, D.R., Fenger, M., Snell, C.R., and Loh, Y.P. 
[1995]. Identification of the sorting signal motif within pro-opiomelanocortin for the 
regulated secretory pathway. J Biol Chem 270, 8723-8729). Located of the two mutations 
are indicated as C28F and L37F.  
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Figure 4-5. The N-terminal peptide (NT) of POMC carries the sorting signal motif which 
directs POMC to the regulated secretory pathway.  The sorting motif is made up of 13 
amino acid residues from codons 34 to 46, forming a hairpin loop structure at the N-
terminus held by two disulfide bridges (between Cys28 and Cys50, and Cys34 and 
Cys46), and disruption of this structure leads to mis-sorting.  This motif is amphipathic, 
with four highly conserved hydrophobic and acidic amino acids (Asp36-Leu37-Glu40-Leu44) 
thought to be vital for the sorting function (Cool et al., 1995; Cool et al., 1997).  The 
mutation Cys28Phe resulted in the loss of the outer disulphide bridge, while Leu37Phe 
led to the loss of the highly conserved Leu37 residue of the amphipathic motif.   
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Mutant POMCs were less efficiently processed  
To study the effect of the mutations on the maturation and of POMC and processing to its 
derivative peptides, biosynthetic studies were performed in transfected β-TC3 cells 
labelled for one hour with 35S-methionine (figure 4-6). Cell lysates were 
immunoprecipitated with an antibody directed against the carboxyterminal c-Myc tag and 
therefore recognizing the uncleaved POMC precursor and the cleavage products β-LPH 
and β-endorphin, the most C-terminal cleavage products. A striking reduction in β-
endorphin and to a lesser extent of β-LPH was observed with the Cys28Phe mutant as 
compared to wild type POMC. A similar, but less severe reduction was also observed 
with the Leu37Phe mutant. β-LPH is generated by PC1 activity starting in the golgi 
network and proceeding into the immature secretory granules and dense core secretory 
granules, and β-endorphin production is typically a late event starting after sorting into 
immature secretory granules and large dense core vesicles.  These results indicate that for 
both POMC mutants, newly synthesized POMC is less efficiently processed into 
bioactive peptides than is the case with wild-type POMC.  
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Figure 4-6. Cys28Phe and Leu37Phe mutations impair the intracellular generation of 
POMC products. Immunoprecipitation of radiolabelled C-terminally Myc-tagged POMC-
derived peptides from β-TC3 cells expressing wild-type POMC and mutant POMCs with 
Cys28Phe and Leu37Phe.  Cys28Phe and to a lesser extent Leu37Phe mutant POMCs 
were processed less efficiently to β-lipotropin (β-LPH) (13 kDa) and β-endorphin (β-end) 
(4 kDa).   Wt=wildtype POMC; control = cells tranfected with empty vectors. 
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As the N-terminus of POMC has been shown to be important for sorting of POMC into 
dense-core granules (Tam et al., 1993), our collaborator A/Prof Creemers undertook 
studies designed to examine the effects of the N-terminal mutations on POMC sorting. 
POMC-derived peptides are secreted via both constitutive and regulated secretory 
pathways. Stimulated secretion of POMC products from endocrine cells occur by fusion 
of dense core granules (DCG), the most mature element of the regulated secretory 
pathway, with the plasma membrane. Stimulus–independent secretion of POMC related 
products occurs through the constitutive secretory pathway. β-TC3 cells which 
endogenously express PC1 and PC2 (and engineered to overexpress PC2 and 7B2 to 
improve processing efficiency) were transfected with wild-type or mutant POMC and 
incubated in serum-free medium for 16 hrs to minimise tonic release of POMC by serum 
factors. Cells were then exposed to fresh serum-free medium for three hours and 
subsequently with serum-free medium containing forskolin and IBMX for three hours 
after which the conditioned medium and cell lysates was assayed for alpha-MSH.  The 
absolute amount of αMSH was significantly reduced with the C28F mutant (figure 4-7A) 
compared to wild type POMC. This was particularly true for the stimulated release but 
also reduced in the medium from unstimulated cells and in the cell lysates. The results for 
the L37F variant displayed the same trend. 
 
 In parallel transfections, the presence of C-terminally myc-tagged POMC was 
used to analyse the processing by western blotting. In the case of wild-type POMC, in the 
absence of a stimulus for regulated secretion, mainly POMC and some β-LPH were 
secreted (figure 4-7B).  
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Figure 4-7. Effects of C28F and L37F on constitutive and regulated secretion of POMC 
products (A) β-TC3 cells transfected with wild type POMC or C28F or L37F mutations 
were incubated in unstimulated medium (M-), or medium with forskolin and IBMX (M+) 
to stimulate release of peptides from the regulated secretory pathway. Cell lysates (L) 
were collected after the stimulation period. The Cys28Phe variant resulted in much less 
α-MSH, and that of the Leu37Phe variant is intermediate between wild-type and 
Cys28Phe.  (B) Parallel transfections utilized the Myc-Tag on the C-terminal of POMC 
for Western blotting of samples from medium without secretagogues (M-); medium with 
secretagogues (M+) and lysates (L).  Cys28Phe POMC and to a lesser extent Leu37Phe 
POMC were not sorted as efficiently as wild-type POMC, with less β-LPH and β-end 
detected.  β-LPH secretion was not increased by secretagogues, indicating that it was 
mainly processed before sorting, and was constitutively secreted, whereas β-end was 





After the addition of secretagogues, a large increase in the secretion of β-
endorphin was observed in the cells transfected with wild-type POMC, while levels of 
secreted POMC and β-endorphin remained the same. These results support the notion 
that secreted β-endorphin is an appropriate marker for POMC’s normal entry into, and 
processing within, the regulated secretory pathway.  With the Cys28Phe mutant the 
amount of POMC secreted under basal and constitutive states was similar to that seen 
with wild type, but smaller amounts of β-LPH and β-endorphin were secreted in both 
conditions (figure 4-7). Importantly, the relative amounts of β-endorphin vs POMC 
detected in the medium after exposure to secretagogues indicates that considerably less of 
the mutant POMC is entering the mature elements of the regulated secretory pathway 
thus suggesting that this mutant POMC is, at least in part, mis-targeted within the cell. 
Similar, but less marked, results were seen with L37F. In the case of this mutant, 
however, there was a small but consistent increase in β-LPH in the medium after 
stimulation by secretagogues, a phenomenon that did not occur with wild-type POMC or 
C28F. These results as a whole suggest that these mutations in the N terminus of POMC 
do not influence the synthesis or steady state amounts of POMC propeptide produced. 
However they both (Cys28Phe > Leu37Phe) impair the processing of the mutant 
propeptide to mature bioactive peptides. Given the distance of the mutants from the main 
processing sites the most parsimonious explanation for this is that the mutations interfere 
with the entry of POMC to the normal regulated secretory pathway, a finding consistent 
with previous studies of artificial mutants in this region of the molecule (Cool et al., 




The melanocortin products of the POMC gene are involved in a wide range of biological 
processes from adrenal steroidogenesis to skin pigmentation (Bertagna, 1994). POMC 
derived peptides appear to be essential for normal energy homeostasis in a subset of 
neurons in the arcuate nucleus of the hypothalamus (Schwartz et al., 2000), as mice and 
humans entirely lacking POMC develop hyperphagia and severe obesity despite lacking 
circulating glucocorticoids due to ACTH deficiency (Coll et al., 2004). Since the original 
description of complete human POMC deficiency (Krude et al., 1998) there have been a 
range of reports describing the association of heterozygous missense mutations in POMC 
with an increased risk of obesity (Challis et al., 2002; Dubern et al., 2007; Hinney et al., 
1998; Lee et al., 2006). The vast majority of these missense mutations affect either the 
structure or function of α- or β-MSH, or the cleavage from their precursor. The 
phenotype from loss of function POMC mutations appears to involve an early onset of 
obesity and objective evidence for increased appetite and food intake (Farooqi et al., 
2006; Lee et al., 2006). Both probands carrying the two mutations Cys28Phe and 
Leu37Phe have early onset obesity, and the proband with the Leu37Phe showed 
increased food intake at an ad libitum test meal consistent with loss of melanocortin 
function. While insufficient family members were available to formally assess co-
segregation with these mutations, those who carry the mutations were either overweight 
or obese.  
 
Cys28Phe and Leu37Phe differ notably from previous reported POMC mutations 
associated with obesity in that they do not lie within, or adjacent to, the melanocortin 
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peptides known to have an established role in energy homeostasis (namely α- and β-
MSH), but lie in the N-terminal region of the POMC molecule.  We have shown that 
these mutations caused loss of POMC-derived signalling peptides by a novel mechanism, 
which is impaired sorting and processing of the POMC pro-peptide.  
 
The sorting of proteins to the regulated secretory pathway is still a matter of 
debate (Dikeakos and Reudelhuber, 2007). For POMC it has been shown that the 26 
amino acids immediately downstream to the carboxy-terminal of the signal peptide 
(amino acids 27-52) are sufficient to target a reporter protein to the regulated secretory 
pathway (Tam et al., 1993). As discussed earlier, two disulfide bridges are formed by 
Cys28/Cys50 and Cys34/Cys46 within that sequence (figure 4-5). The hairpin loop 
between Cys28 and Cys50 forms an amphipathic loop and contains highly conserved 
amino acids, in particular Asp36, Leu37, Glu40 and Leu44 (Cool et al., 1995), which 
may be part of a vital sorting signal binding site for the sorting process (Cool and Loh, 
1998). Sorting of POMC is required for efficient processing to its bioactive peptides, 
which starts in the TGN and proceeds in the regulated secretory pathway (Schnabel et al., 
1989). The two main enzymes involved in its processing are the PC1 and PC2. Cleavage 
by PC1 starts in the late Golgi subcompartments and immature secretory granules, and 
results in the generation of β-LPH and some ACTH (Schnabel et al., 1989). PC2 requires 
a more acidic environment and therefore becomes active only upon maturation of the 
immature secretory granules, resulting in the production of melanocortins and β-
endorphin (Pritchard et al., 2002).   
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Sorting of POMC from the trans-Golgi network (TGN) to immature secretory 
granules may be a key regulatory step which determines the extent of POMC processing 
(Pritchard and White, 2007). There are different theories regarding the mechanisms by 
which POMC is sorted and targeted to the regulated secretory pathway.  Currently, the 
majority of studies support a sorting-for-entry model where targeting to granules is 
determined in the TGN (Dumermuth and Moore, 1998). The amino-terminal amphipathic 
loop on POMC is important as a sorting signal motif (Cool et al., 1995), which has been 
proposed to bind to carboxypeptidase E as a putative sorting receptor (Cool et al., 1997). 
Therefore disruption of this region by changes in amino acids (Leu37Phe) is likely to 
impede sorting to secretory granules and the effective processing of POMC to bioactive 
peptides. 
  
Cys28 has previously been mutated by others without observing a deleterious 
effect on sorting (Cool et al., 1995; Roy et al., 1991). This discrepancy with our 
observations can be explained because Cys28 was replaced by the physico-chemically 
similar amino acid serine in these studies. The Cys28Phe mutation results in substitution 
by the much larger phenylalanine with a bulky aromatic side chain (Cys28Phe), which is 
likely to cause steric hindrance and destabilize the overall structure of the hairpin loop 
(figure 4-5).  
 
Leu37 is highly conserved in POMC and the replacement of aliphatic leucine by 
phenylalanine with an aromatic side chain might have been expected to have a severe 
effect. The modest effect observed here might be the consequence of the experimental 
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set-up. POMC sorting is a multi-step process including oligomerization/aggregation in 
the TGN, which is independent of the N-terminal loop (Cawley et al., 2000). Furthermore, 
the influence of each domain might be cell-type specific (Gorr et al., 2001). For instance, 
cell-type specific effects on processing are found in the mouse model carrying a mutation 
in the PC1 gene resulting in a N222D substitution (Lloyd et al., 2006). In this model, 
carboxy-terminal processing of PC1 was much more affected in the hypothalamus than in 
brain and pancreas. The experiments in the current study were performed in pancreatic β 
cells to circumvent the problem of endogenous POMC, but it is possible that the observed 
differences in sorting and α-MSH production are more pronounced in hypothalamic 
neuronal cells. 
 
Csy28Phe and Leu37Phe represent a novel mechanism of disruption of human 
POMC function, and support the notion that the N-terminal component of human POMC 
is important for targeting of the propeptide to the regulated secretory pathway. These 
naturally occurring mutations act as illuminating “experiments of nature”, which validate 
the sequence requirements for normal POMC targeting and processing as demonstrated in 
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Chapter 5 
The role of Melanocortin 3 Receptor Gene in Childhood Obesity 
Summary 
Melanocortin 3 receptor (MC3R) plays a critical role in weight regulation of rodents, but its 
role in humans remains unclear. To identify genetic variants of the MC3R gene and 
determine its association with childhood obesity, we screened 201 obese children for 
MC3R gene mutations, with anthropometric measurements, blood tests, feeding behaviour 
and body composition assessment. We identified three novel heterozygous missense 
mutations (Ile183Asn, Ala70Thr, and Met134Ile) in three unrelated subjects, which were 
not found in 188 controls, and two common polymorphisms Thr6Lys and Val81Ile (single 
nucleotide polymorphisms).  In-vitro functional studies of the resultant mutant receptors 
revealed impaired signaling activity but normal ligand binding and cell surface expression.  
The heterozygotes demonstrated higher leptin levels and adiposity, and less hunger, 
compared to obese controls, reminiscent of the MC3R knockout mice.  Family studies 
showed that these mutations may be associated with childhood or early onset obesity.  The 
common variants Thr6Lys and Val81Ile were in complete linkage disequilibrium, and in-
vitro studies revealed reduced signaling activity compared to wildtype MC3R.  Obese 
subjects with the 6Lys/81Ile haplotype had significantly higher leptin levels, percentage 
body fat, and insulin sensitivity, and the causative role of the 6Lys/81Ile variants is 
supported by the presence of an additive effect, where heterozygotes had an intermediate 
phenotype compared to homozygotes. MC3R mutations may not result in autosomal 
dominant forms of obesity, but may contribute as a predisposing factor to childhood 
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obesity, and exert an effect on the human phenotype. Our study supports the role of MC3R 
in human weight regulation. 
 
Introduction 
The melanocortin pathway mediates leptin action and regulates energy balance by 
inhibiting feeding, increasing energy expenditure and reducing energy storage.  The 
Melanocyte Stimulating Hormone (MSH) is the principal agonist of the neuronal 
melanocortin receptors, melanocortin 3 receptor (MC3R) and melanocortin 4 receptor 
(MC4R), both of which are critical for weight regulation in rodents (Butler et al., 2000; 
Chen et al., 2000; Huszar et al., 1997).   
 
MC3R is a seven-transmembrane G-protein coupled receptor (Gantz et al., 1993a) 
expressed in hypothalamic nuclei known to regulate energy homeostasis.  It exhibits a 
more restricted distribution than MC4R in the central nervous system (Roselli-Rehfuss et 
al., 1993), and has a dominant role in inhibition of energy storage (Butler et al., 2000; 
Chen et al., 2000).  Mc3r-/- mice homozygous for knockout mutations of MC3R gene had 
increased body fat (Butler et al., 2000; Chen et al., 2000) not caused by increased food 
intake but by increased feed efficiency.  The Mc3r-/- mice were hypophagic with 
hyperleptinemia compared to wildtype littermates (Chen et al., 2000).  These mice were 
unusually susceptible to high fat diet-induced obesity, and were relatively inactive, which 
partly explained the obesity.  The mice showed no perturbations in metabolic rate, 
thyroid hormone levels, respiratory exchange ratio or body temperature.  Male mice 
developed mild hyperinsulinaemia. Mice lacking both MC3R and MC4R have 
  110
exacerbated obesity, which supports the notion that both are important and non-redundant 
(Chen et al., 2000).     
 
MC4R mutations causing human obesity are well described (Farooqi et al., 2003; 
Vaisse et al., 2000), but the search for human MC3R mutation has been largely 
unsuccessful (Feng et al., 2005; Hani et al., 2001; Li et al., 2000; Schalin-Jantti et al., 
2003; Yiannakouris et al., 2004). In this chapter, we report three novel missense 
mutations in three unrelated probands, as well as the association of the common MC3R 
variants with obesity related phenotypes in our cohort of obese children (Lee et al., 
2007b; Lee et al., 2002). 
 
Methods 
Study subjects and assessment 
The MC3R gene was analysed in 201 unrelated children and adolescents with early onset 
severe obesity, recruited from the general clinics of the nationwide School Health Service.  
Inclusion criteria were percentage ideal weight for height (WFH) of more than 140%, and 
onset of obesity before 6 years of age.  There were 128 boys (63.7%); ethnic distribution 
was as follows: Chinese 105 (52.2%), Malay 69 (34.3%), Indian 21 (10.4%) and Others 6 
(3%).  The mean (SD) age was 11.1 (3.0) years, WFH 170.5 (22.7) %, BMI 31.9 (5.5) 
kg/m2, and % body fat 40.7 (5.2) % by dual energy x-ray absorptiometry (DEXA) or 45.7 
(9.1) % by bipedal bioimpedance analysis for body fat composition (BIA).  This research 
was approved by our hospital’s Research and Ethics Committee, and informed written 
consent was obtained from all subjects and parents.   
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 Blood samples were obtained in the fasted state.  Leptin was measured using DSL-
10-23100 Human Leptin Enzyme-Linked Immunosorbent Kit (Diagnostic Systems 
Laboratories, Texas).  Insulin resistance was calculated using the homeostasis model 
assessment (HOMA) (Matthews et al., 1985), and insulin sensitivity by Quantitative Insulin 
Sensitivity Check Index (QUICKI) (Katz et al., 2000).  Bone density and body fat 
composition were assessed using DEXA (Norland DEXA model XR-36, Fort Atkinson, 
Wisconsin).  BIA was performed using the portable Tanita Body Composition Analyzer 
(TBF-300GS, Tanita Corporation, Tokyo).      
 
Qualitative food-intake evaluation was performed using the Three-Factor Eating 
Questionnaire, a psychometric instrument to study eating behaviour, measuring three 
dimensions: restraint, disinhibition and hunger (Stunkard and Messick, 1985).  Restrained 
eating is defined as the tendency to restrict food intake in order to control body weight.  
Disinhibition is the inability to resist emotional and social eating cues.  Hunger is the 
subjective feeling of hunger.  Numeric scores for each of the three factors were derived 
for each subject.  Data concerning estimation of their physical activities were also 
obtained by using a physical activity questionnaire modified from the Modified Activity 
Questionnaire for Adolescents and validated in our local population (Aaron et al., 1995; 
Schmidt et al., 1998), and each subject was categorized depending on physical activity 
for the past month: categories 1 (inactive), 2 (relatively inactive), 3 (light physical 




Genomic DNA was extracted from peripheral leukocytes using standard techniques.  The 
single exon was amplified by polymerase chain reaction (PCR) using the following 
primers: forward primer 5’-GGGAGACAGAAGGAAGACAGC-3’, and reverse primer 
5’-GAGCAGATGAGCAGACAGGC-3’.  The PCR was performed with a thermal cycler 
using the following conditions: denaturation at 95oC for 3 minutes, followed by 35 cycles 
of denaturation at 95oC x 45 seconds, annealing at 57oC x 45 seconds, elongation at 72oC x 
1 minute, followed by final elongation at 72oC for 5 minutes.   The amplicons were directly 
sequenced in 2 fragments using the following sequencing primers: 5’-
TCTCTCTACCCTCCCCATCC-3’ and 5’-TGCAACCTCCTGGCCATCGC-3’.  
Sequencing was performed using dRhodamine Terminator Cycle Sequencing Kit (PE 
Applied Biosystems) and analysed on the ABI 377 automated sequencer. All mutations 
found were verified by reverse sequencing. 
 
 Three novel mutations, Ile183Asn, Ala70Thr, and Met134Ile were found during the 
screening process.  188 genomic DNA samples from 99 healthy children with normal 
height and weight [mean age (SD) = 7.1 (4.6) years; mean BMI (SD) = 16.8 (3.4) kg/m2; 
63 males], and 89 healthy adults (mean BMI < 25 kg/m2, 30 males) were analysed as 
normal controls.  The three novel mutations were not found in these 188 normal controls.  
Allele-specific PCR for Ile183Asn was used to amplify mutant MC3R gene with Ile183Asn 
(T548A) in these control samples.  Allele-specific PCR was also used to study the pedigree 
with the mutation.  Multiplex PCR by concomitant PCR amplification of a marker DNA is 
performed to exclude PCR failure (a short fragment of MC4R gene).  Primers for mutant-
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specific PCR for Ile183Asn: forward primer 5’-TCTCTCTACCCTCCCCATCC-3’, 
reverse (selective) primer 5’-GTA GCGGAGCGCGTAAAAGT-3’.  Primers for marker 
DNA: forward primer 5’-CTGCTTTCAATTGCAGTGGA-3’, reverse primer 5’-
ATGGTCAAGGTAATCGCTCC-3’.  PCR conditions: denaturation at 95oC for 3 minutes, 
followed by 35 cycles of denaturation at 95oC x 45 seconds, annealing at 54oC x 45 
seconds, elongation at 72oC x 45 seconds, followed by final elongation at 72oC for 5 
minutes. The other methods used are restriction enzyme digest using Hha I for Ala70Thr 
(G208A) and allele-specific PCR for Met134Ile using similar conditions as above.  
 
 Two common variants Thr6Lys and Val81Ile were always found together, and we 
confirmed they resided on the same allele (haplotype) in the heterozygotes.  Allele specific 
PCR of Thr6 and Lys6 alleles were performed using selective forward primers, and 
amplified DNA was then incubated with BseDI.  Only amplicons with Val81 (triplet GTT) 
would be cut. 
 
In-vitro receptor function studies 
Construction of MC3R plasmids and expression 
Wild type, variant (Thr6Lys and Val81Ile) and mutant MC3R (Ala70Thr, Met134Ile and 
Ile183Asn) were directly amplified from individual genomic DNA using Pfx DNA 
Polymerase (Invitrogen Life Technologies, Carlsbad, CA).  Forward and reverse primers 
were designed with Hind III and Xba I enzyme restriction sequences at the 5’ end. The 
Renilla luciferase reporter gene was amplified from the phRG-TK reporter vector 
(Promega Corp, Madison, WI) with a pair of primers containing the Kpn I and Xho I 
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restriction sites at the 5’ end. All generated amplicons were TA cloned into the pDrive 
vector using the QIAGEN PCR Cloning Plus Kit (Qiagen GmbH, Hilden, Germany).  
 
All MC3R inserts were excised from the pDrive/MC3R constructs using Hind III 
and Xba I, and ligated into the pBudCE4 mammalian dual expression vector (Invitrogen 
Life Technologies, Carlsbad, CA) under the control of the CMV promoter while the 
Renilla luciferase reporter gene was ligated into the Kpn I and Xho I site of the vector under 
the control of the EF-1α promoter.  For creating stable cell lines expressing the receptors, 
amplified MC3R gene was TA cloned into the pcDNA5/FRT/V5-His vector (Invitrogen 
Life Technologies, Carlsbad, CA).   
 
One day prior to transfection, subconfluent Griptite human embryonic kidney cells 
(Invitrogen Life Technologies, Carlsbad, CA) were trypsinized and seeded in 96-well 
plates at a density of 1x104 cells/well. Transient transfection was performed using the 
Effectene transfection reagent (Qiagen GmbH, Hilden, Germany) with 90 ng pCRE-Luc 
(Stratagene, La Jolla, CA) and 10 ng pBudCE4/MC3R/Renilla construct per well.  
 
Stably expressed MC3R cells were created with the Flp-In System (Invitrogen Life 
Technologies, Carlsbad, CA) as recommended by the manufacturer. Briefly, 
pcDNA5/FRT/V5-His/MC3R and pOG44 vectors were transfected into Flp-In 293 cells at 
a ratio of 9 to 1. After 48 hours, the cells were trypsinized and seeded into T75 flasks 
containing complete DMEM media and 100 ug/ml hygromycin B for selection.   
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MC3R stimulation, luciferase assay, and dimerisation 
24 hours after transient transfection, cells were washed with PBS and stimulated with α-
MSH (Sigma-Aldrich, St. Louis, Missouri, USA) with concentrations ranging from 1 pM 
to 1 uM in DMEM media containing 0.2% BSA for 6 hours.  Cells were then washed and 
lysed with 1x passive lysis buffer, then assayed for luciferase activity using the Dual 
Luciferase Reporter Assay System (Promega Corp, Madison, WI) in the TD-20/20 
luminometer (Turner Biosystems Inc, Sunnyvale, USA). cAMP induced firefly luciferase 
readings from pCRE-Luc expression were normalized with Renilla luciferase readings 
expressed from the pBudCE4/MC3R/Renilla plasmid construct. Normalized luciferase 
readings were then expressed as fold activity over basal (non-stimulated transfected cells). 
Data points were fitted by non-linear regression analysis using GraphPad Prism software 
(version 4.00 for Windows, GraphPad, San Diego, California, USA).   
 
To investigate effects of receptor dimerization between wild type and mutant 
receptors, stable cells expressing wild type receptors were transfected with 
pBudCE4/mutant constructs, pCRE-Luc and phRG-TK reporter vector. Receptor 
stimulation and luciferase assay were then performed similarly as above. 
 
Membrane preparation 
Stable cell lines expressing receptors were grown in selective media until subconfluent. 
Cells were washed with ice cold PBS and scraped off, pelleted, then resuspended in 2 mls 
of ice cold homogenization buffer (20 mM HEPES, pH 7.0, 1 mM MgCl2, 1 mM EDTA, 1 
mM PMSF). The cell suspension was homogenized in Dounce glass homogenizer on ice.  
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The homogenate was centrifuged at 1700xg for 10 minutes at 40C, the supernatant was then 
collected, and centrifuged at 40,000xg for 40 minutes at 40C.  The pellet containing crude 
cell membranes was then resuspended in homogenization buffer, aliquoted and stored at –
800C immediately. Protein concentration of crude membranes was determined using Bio-
Rad’s Protein Assay reagent (Bio-Rad, Hercules, CA) with BSA as the standard. 
 
Receptor binding studies 
Binding studies were performed using time-resolved fluorometry (TRF) technology with 
europium labeled ligand. 24 hours after transient transfection in 96-well plates, cells were 
washed once in PBS and incubated for two hours with increasing concentrations of 
europium labeled NDP-αMSH (PerkinElmer, Boston, MA) in binding buffer (25 mM 
HEPES, pH 7.0, 1.5 mM CaCl2, 1 mM MgSO4, 100 mM NaCl, 25 uM EDTA, 0.2% BSA).  
Non-specific binding was determined in the presence of 3 μM unlabeled NDP-αMSH. 
After incubation, cells were washed four times with wash buffer (50 mM Tris-Cl, pH 7.5, 5 
mM MgCl2) and incubated with 100 uL/well of DELFIA Enhancement Solution 
(PerkinElmer, Boston, MA) at room temperature for 15 minutes. Fluorescence were 
measured in the Wallac Victor2-V 1420 multilabel HTS counter (PerkinElmer, Boston, 
MA) fitted with filters for europium TRF measurements.  
 
Saturation studies using crude cell membranes were performed similarly in 100 ul 
of HEPES binding buffer using 2 ug of membrane protein, in Acrowell filter plates (Pall 
Corp, East Hills, NY). Reactions were terminated by rapid filtration using a vacuum 
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manifold with four washes of wash buffer before the addition of the DELFIA enhancement 
solution. 
 
Competitive ligand binding studies were performed in 100 ul of HEPES binding 
buffer containing 2 ug of crude membranes,  europium labeled ligand at a concentration 
close to the Kd values and competitor ligands (NDP-αMSH and α-MSH). Incubation 
conditions were similar as for saturation studies and plates were processed as described 
above.  
 
Immunofluorescence staining of MC3R  
Griptite 293 cells grown on glass coverslips were transiently transfected with 200 ng of 
pBudCE4/MC3R/Renilla using the Effectene reagent. After 48 hours incubation, the cells 
were washed once in PBS and fixed with 3.7% paraformaldehyde for 15 mins at room 
temperature. The cells were washed three times with PBS and then incubated with 
blocking buffer (5% BSA, 2% FBS) for 30 minutes at room temperature. After rinsing in 
PBS, cells were incubated with polyclonal rabbit anti-MC3R IgG (Santa Cruz 
Biotechnology, Santa Cruz, CA) in 1% BSA for 2 hours at room temperature. Cells were 
washed 4 times with PBS and then incubated with goat anti-rabbit IgG conjugated with 
Alexa fluor 488 dye (Molecular Probes Inc, Eugene, OR) in 1% BSA for 1 hour at room 
temperature. Cells were then subjected to 5 washes with PBS and coverslips were 
mounted with ProLong Gold Antifade reagent (Molecular Probes Inc, Eugene, OR). 




Comparison of parameters was performed with Student’s t test, General Linear Model with 
covariates analyses to adjust for age, gender and ethnicity, One way ANOVA trend 
analysis, Mann Whitney U test, Fisher’s exact test and chi-square test where appropriate 
(SPSS Inc., Chicago, Ill., USA).  Graph fit curves and EC50/IC50 were obtained and 
performed using GraphPad Prism 4 for Windows (ver 4.02 GraphPad software, San Diego, 
California, USA), and curves were fitted using the logistical equation.  Ki values were 




We found three rare variants or potentially novel missense mutations, Ile183Asn (T548A), 
Ala70Thr (G208A), and Met134Ile (G402A), in the heterozygous state in three unrelated 
subjects (figures 5-1A, B and C), as well as two common variants Thr6Lys and Val81Ile.  
The three potentially novel mutations Ile183Asn, Ala70Thr, and Met134Ile were not found 
in 188 non-obese normal controls.   
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Figure 5-1 A.  Sequencing of the MC3R gene in the proband revealed T to A transition in 
heterozygous state at nucleotide position 548 (N), leading to the substitution of isoleucine 
by asparagine at codon position 183.  B. G to A change in heterozygous state at nucleotide 
position 208 causing change of alanine to threonine at codon position 70.  C. G substitution 
by A in heterozygous state at nucleotide position 402, leading to change of methionine to 




We confirmed the Thr6Lys (17C>A) and Val81Ile (241G>A) variants were in complete 
linkage disequilibrium and located on the same allele (haplotype) in our cohort and 
normal controls.  Of 198 subjects (excluding the three with novel variants), 121 were 
homozygous for the wildtype allele, 70 subjects were heterozygous, and 7 subjects were 
homozygous for the allele (haplotype) with common variants.  88 DNA samples from the 
99 non-obese children (controls) were randomly selected for genotyping for the common 
variants, and 5 DNA samples failed to yield satisfactory PCR products or sequence 
readings.  Among these 83 non-obese children, 31 were found to be heterozygous and 2 
homozygous for the 6Lys/81Ile haplotype (henceforth identified as 6K/81I).  No 
significant difference in genotypic frequencies was detected when compared to the obese 
group (p=0.843).     
 
Obese subjects with 6K/81I had significantly higher leptin levels, percentage body 
fat, and insulin sensitivity index QUICKI, with lower insulin resistance index HOMA.  The 
causative role of the 6K/81I variants is further supported by the presence of an additive 
effect, where the heterozygotes had an intermediate phenotype compared to homozygotes 
(table 5-1).   
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Table 5-1. Additive effect of the 6K/81I variants on the adiposity, leptin levels and insulin 
resistance indices, in (A) all subjects, and (B) Chinese subjects. 
(A) all subjects    





N 121 70 7 - - 
Age (years) 11.0 (3.0) 11.2 (3.0) 12.2 (3.5) - 0.371 
(ns) 




Leptin (mcg/L) 45.4 (31.3) 54.9 (37.9) 82.6 (64.8) 0.041 <0.001 
body fat (%) 44.4 (9.0) 48.7 (8.7) 54.1 (14.5) 0.002 <0.001 
HOMA 5.180 (1.914) 5.076 (2.397) 2.707 (2.060) 0.031 0.042 
QUICKI 0.303 (0.025) 0.306 (0.035) 0.331 (0.035) 0.016 0.047 
 
All values are expressed as mean (standard deviation).  
#General linear model with age, gender and race as covariates  
+One-way ANOVA trend analysis.   
  122
(B) Chinese subjects 





N 64 38 3 - - 
Age (years) 11.5 (3.0) 11.6 (2.7) 12..0 (2.4) - 0.71 
WFH (%) 167.3 (18.0) 165.0 (19.0) 166.0 (15.4) 0.841 0.818 
Leptin (mcg/L) 41.5 (31.5) 45.1 (32.7) 48.8 (4.0) 0.07 0.091 
body fat (%) 44.4 (8.9) 48.8 (8.7) 55.3 (13.3) 0.002 <0.001 
HOMA 5.975 (1.851) 5.701 (1.944) 2.494 (1.576) 0.018 0.069 
QUICKI 0.297 (0.023) 0.299 (0.025) 0.334 (0.023) 0.009 0.038 
All values are expressed as mean (standard deviation).  
#General linear model with age and gender as covariates.  
+One-way ANOVA trend analysis.   
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In addition, the obese subjects heterozygous and homozygous for 6K/81I had 
significantly lower triglyceride levels (1.19 + 0.50 mmol/L vs. 1.41 + 0.73 mmol/L, 
p=0.012) and lower fasting glucose levels (4.4 + 0.5 mmol/L vs. 4.8 + 0.8 mmol/L, 
p=0.024) compared to obese subjects with wildtype MC3R alleles.  We did not detect any 
significant differences in other parameters, including insulin and c-peptide levels, insulin-
glucose ratios, frequency of diabetes mellitus/impaired glucose tolerance, physical 
activity pattern, or feeding behaviour scores.  Our clinical findings are supported by in-
vitro studies which revealed a modest but significant decrease (p<0.01) in maximal 
activity of the MC3 receptor with variants 6K/81I compared to wildtype MC3 receptor 
(figure 5-2A), without any significant difference in binding affinity to α-MSH or NDP-
MSH (figure 5-2E).  Based on the MC3R knockout mouse model, reduced MC3 receptor 
activity is expected to lead to increased body fat (feed efficiency), and leptin levels 
(Butler et al., 2000; Chen et al., 2000). 
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Figure 5-2.  Constructs with wildtype and variant MC3R were co-transfected with pCRE-
Luc into HEK293 cells and stimulated with varying amounts of α-MSH. Y axis represents 
the fold increase over basal Relative Light Units (RLU), which is the ratio of luminescence 
generated by Firefly luciferase (from pCRE-Luc) to Renilla luciferase (from 
pBudCE4/Renilla/MC3R construct); the data is expressed as such to normalize for 
transfection efficiency and amount of MC3R produced.  This represents the amount of 
cyclic AMP generated with increasing concentration of the ligand α-MSH (represented by 
x-axis). Each data point represents the mean and standard error range of at least 3 
independent experiments performed in triplicates.   A.   There is a significant reduction in 
6K/81I MC3 receptor compared to wildtype (normalized fold activity over basal 94.42 
[95% CI 88.26 – 100.6] vs. 106.2 [95% CI 102.4-110.1]; p<0.01)   B.  There was severely 
impaired generation by the Ile183Asn mutant MC3 receptor (with 6K/81I) compared to the 
MC3R with 6K/81I.  The Met134Ile mutant MC3 receptor (with 6K/81I) dose response 
curve is shifted to the right, with a significantly higher EC50 value compared to receptor 
with 6K/81I (2.051x10-9 [95% CI 1.358x10-9 – 3.097x10-9] vs. 7.408x10-10 [95% CI 
5.008x10-10 – 1.096x10-9]; p=0.0005). C. Ile183Asn mutant receptor actually exhibits a 
small response to MSH stimulation. Note magnified scale of y-axis.  D. Ala70Thr mutant 
receptor has significantly reduced response to MSH stimulation compared to wildtype 
MC3R (normalized fold activity 92.7 [95% CI 86.0-99.3] vs. 106.2 [95% CI 102.4-110.1]; 
p<0.01).  E. Competitive ligand binding studies using crude membranes and europium 
labeled NDP-MSH at a concentration close to the Kd values and competitor αMSH.  Data 
is expressed as a percentage of the maximum counts of europium labeled NDP-αMSH 
binding to MC3R. Each point represents the mean and standard error range of at least 6 





This novel mutation was found in an Indian family, and is the first report of human MC3R 
mutation (Lee et al., 2002).  A 13-year-old Indian girl (proband) with early onset severe 
obesity was heterozygous for this mutation (figure 5-3A).  She was first screened at 13 
years of age, when she already had severe obesity (WFH 182%) and irregular menstrual 
cycles due to clinically diagnosed polycystic ovarian syndrome.  The proband and her 
father who was also heterozygous for the same mutation did not have any distinguishing 
phenotype.  Although the proband’s percentage body fat was excessive at 49%, it was not 
distinguishing, when compared to other obese patients in general.  Her dietary history was 
not suggestive of excessive caloric intake, and despite careful dieting she continued to gain 
weight.  Although she had tried to engage in regular physical exercises, she was not able to 
sustain her efforts.  These aspects are reminiscent of the Mc3r-/- mice.  The father was 
previously very obese, but he was more motivated and had engaged in weight losing 
measures successfully.  His WFH was 157% but percentage body fat was only 30% by 
DEXA; but there was significant hypertriglyceridemia. Her mother and younger brother 
without the Ile183Asn mutation were available for evaluation at that time, and both were 
also obese (WFH 170% and 132% respectively), and thus it was impossible to study 
genotype-phenotype co-segregation.  Obesity is such a common condition that, and even 
within a given family, a varying combination of environmental, behavioural and multiple 
genetic factors other than MC3R mutation can be contributory.  Four years later, at 17 years 
of age, the proband was re-evaluated and found to have developed morbid obesity with 
high percentage ideal body weight for height (WFH) of 216%, and percentage body fat 
(%BF) of 71%.  Her heterozygous father’s WFH has increased to 167%, and %BF was 
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48%.  The proband was the most overweight of the family with the highest %BF.  The 
eldest sibling (not available for the first evaluation four years ago) was found to be 
heterozygous for this mutation.  At 23 years old, he was not obese, with BMI of 23.5 
kg/m2.  However, he was overweight as a child.  At 7 years old, his weight was 
documented as 27 kg with WFH of 125% (>120% defined as mild obesity).  He only 
started to lose weight in his teenage years as he was physically active, and underwent army 
training for two years.  He has since maintained a very active lifestyle with regular exercise 
and sports, and is careful with his diet.  The paternal uncles and aunt had late onset obesity 
or overweight phenotypes, and genotyping revealed wildtype MC3R alleles.  An interesting 
observation was the co-segregation of early onset childhood obesity with the mutant MC3R 
allele (figure 5-3A).  Among the four siblings (paternal uncles and aunt), the proband’s 
father was the only one who was obese since early childhood.  His documented weight and 
BMI at 16 years were 86 kg and 33 kg/m2.  The other three sibs were overweight only after 
30 years of age: the eldest uncle was 64 kg at 18 years of age, and second uncle was 60 kg 
at 20 years old.   
  128
Figure 5-3.  Family pedigrees of affected subjects with MC3R mutations.  The age (in 
years), body mass index (BMI), percentage of ideal weight for height (WFH), and 
percentage body fat (%BF) are listed.  Heterozygotes are half-shaded.  Subjects with 
history of childhood or early onset obesity are highlighted with asterisk (*).  A. Family 
with Ile183Asn mutation.  B. Family with Ala70Thr mutation.  C. Family with Met134Ile 
mutation.   
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Ala70Thr 
The Ala70Thr mutation was found in an 11-year-old boy and his mother (figure 5-3B).  
The proband was overtly obese, whereas his heterozygous mother had mild obesity (% wt 
for ht 121%).  His mother was overweight as a child, but documented weight and height 
measurements were unavailable.  She has been careful with her diet and exercises 
regularly, as she is very conscious of her weight and body image. 
 
Met134Ile 
The heterozygous Met134Ile mutation was found in a 12-year-old Indian girl and her obese 
mother, and both mother and child have type 2 diabetes mellitus (figure 5-3C).  The 
proband was asymptomatic but was diagnosed by abnormal oral glucose tolerance test.     
 
 The 3 probands were compared to groups of obese controls of similar age and same 
gender as shown in table 5-2.  The controls selected were 2-3 years younger or older than 
the subjects with rare variants.  This age range was chosen arbitrarily to include a sizeable 
number of controls for this comparison.   All subjects who fulfilled the criteria are included 
in the analysis. The probands had significantly higher leptin levels (p=0.018), and also 
appeared to have higher BMI, WFH and %BF, although these did not reach statistical 
significance.  We also observed that heterozygotes had significantly lower Hunger scores 
(less subjective feeling of hunger) compared to that of the obese controls (p=0.026) (table 
5-3).  The scores for Restrained Eating and Disinhibition were not significantly different 
between the heterozygotes and the obese controls without MC3R mutations (p >0.05 for 
each factor analysed). This is reminiscent of the MC3R knockout mice which were 
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hypophagic with high leptin levels and body fat mass (Butler et al., 2000; Chen et al., 
2000).  We did not detect any significant difference in HOMA or insulin/glucose ratio, or 
physical activity levels.  
 
Impaired signaling activities of the mutant receptors 
As wildtype MC3R and MC3R with common variants 6K/81I (haplotype) showed 
significant differences in response to α-MSH stimulation (Feng et al., 2005), we compared 
the signaling properties of the mutant MC3Rs to the corresponding MC3R with or without 
6K/81I.  This is also in consideration of possible conformational changes induced by 
interaction of these variants.  The Ile183Asn and Met134Ile mutant alleles of our two 
subjects carried the 6K/81I (haplotype) concomitantly, and were thus compared to MC3R 
with 6K/81I (haplotype) in our transfection studies.  This was determined by cloning each 
of the two MC3R alleles from the subject’s DNA sample into pDrive vector followed by 
direct sequencing, and also by allele-specific PCR for Lys6 followed by direct sequencing 
as described above. 
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Table 5-2.  Comparison of the age, body mass index (BMI), percentage ideal weight for 
height (WFH), waist-hip ratio (WHR), and  percentage body fat (%BF) of each proband 
with a group of controls of similar age, same gender, and 6K/81I carrier status.   
 













11.9 11.1  
(3.2) 
11.7 11.1  
(1.3) 









31.6 30.7  
(3.6) 






















WHR 0.990 0.890 
(0.072) 









%BF 57.3 47.0  
(6.7) 


























Values expressed as mean (standard deviaton). 
† Females selected based on age 3 years above or below 11.9 years, and heterozygous for 
6K/81I, as subject with Met134Ile is heterozygous for 6K/81I.  
‡Males selected based on age 2 years above or below 11.7 years, and with wildtype MC3R 
alleles 6T/81V, as subject with Ala70Thr is homozygous for wildtype allele.  
§Females selected based on age 2 years above or below 13.1 years, and homozygous for 
6K/81I, as subject with Ile183Asn is homozygous for 6K/81I.  
All controls that fulfilled age criteria are included in the analysis. 
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Table 5-3.  Feeding behaviour assessment of the three probands and obese heterozygote 
parents, compared to obese controls without MC3R mutations.   
 





















Restraint 9 (0-20) 11 16 7 9 11 11 (7-16) 
Disinhibition 7 (0-14) 2 8 6 4 6 6 (2-8) 
Hunger 7 (0-14) 3 4 7 3 2 3 (2-7)* 
Scores expressed as median (range). 
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 Both transient and stable (not shown) transfection studies revealed severely 
impaired signaling response of the Ile183Asn mutant receptor to α-MSH.  The cells 
transiently expressing the mutant MC3 receptor Ile183Asn showed negligible response to 
increasing α-MSH concentration (figures 5-2B and C).  Mutant receptor Met134Ile 
demonstrated a modest but significantly higher EC50 compared to MC3R with 6K/81I 
(figure 5-2B).  The mutant Ala70Thr receptor also demonstrated significantly reduced 
cAMP response to MSH stimulation (figure 5-2D).  Our competitive ligand binding studies 
did not find any significant differences in IC50 between the wildtype, 6K/81I, Ala70Thr, 
Met134Ile and Ile183Asn MC3 receptors (figure 5-2E).  The three mutant MC3 receptors 
did not exert any dimerisation effect on wildtype or 6K/81I MC3 receptors (figure 5-4).  
The findings were similar using NDP-MSH instead of α-MSH (data not shown).  
Immunofluorescence staining of HEK cells transiently transfected with these variant MC3 
receptors revealed good level of cell surface expression comparable to wildtype MC3R 
qualitatively (figure 5-5).         
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Figure 5-4 Mutant MC3 receptors were transfected into stable cell lines expressing a. 
wildtype MC3R. b MC3R with 6K/81I.  There was no significant reduction in cAMP 
generation by these cells to suggest dimerisation as a result of concomitant expression of 
the mutant receptors.  
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Figure 5-5.  Cell surface expression of MC3R detected by immunofluorescence staining. 
Griptite 293 cells were grown in coverslips and transiently transfected with indicated wild 
type and variants. Cells were not permeabilized and stained with anti-MC3R antibody 




Common obesity is a polygenic trait resulting from interaction of multiple genetic loci 
with the environment.  Sequence variants in a large set of genes implicated in energy 
regulation could predispose an individual to excessive weight gain in a given 
environment.  While MC3R mutations are unlikely to result in an autosomal dominant 
form of monogenic obesity, this study provides evidence that MC3R can be one of the 
predisposing genes which contributes to increased adiposity, and the wide variation in the 
adiposity of the individuals with common and rare variants may be due to other 
modifying genetic and environmental factors. 
 
MSH, a derivative of pro-opiomelanocortin (POMC), acts on MC4R and MC3R to 
reduce feeding and feed efficiency.  The Mc3r-/- mice demonstrated mild obesity but 
increased body fat and leptin, while the phenotype of the heterozygous Mc3r+/- mice did not 
appear to differ significantly from wildtype mice (Butler et al., 2000; Chen et al., 2000).  In 
comparison, the Pomc-/- mice also exhibit an obese phenotype while the heterozygous 
Pomc+/- mice appeared to have a similar phenotype to wildtype mice on standard chow 
(Challis et al., 2004; Yaswen et al., 1999).  However, Pomc+/- mice developed obesity when 
put on a high-fat diet (Challis et al., 2004), exhibiting an intermediate obese phenotype 
between wild-type and Pomc-/- mice, demonstrating that a single functional copy of the 
POMC gene is not sufficient for maintaining normal energy homeostasis under certain 
environmental conditions, and haploinsufficiency can interact with dietary factors to 
increase body weight.  There is evidence to suggest that loss of one POMC allele, and even 
genetic variants with subtle effects on POMC function, could influence susceptibility to 
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obesity in humans in our modern ‘obesogenic’ environment. Heterozygous parents of obese 
children homozygous for POMC null mutations had high normal to high BMI (Krude et al., 
2003), and other family members heterozygous for POMC null allele were more 
overweight than those with wildtype alleles (Farooqi et al., 2006). Heterozygous partially 
inactivating POMC mutations Arg236Gly and Tyr221Cys were also found more frequently 
in obese children, and the phenotype is reminiscent of MC4R deficiency (Challis et al., 
2002; Lee et al., 2006).  Therefore, partially inactivating genetic variants of MC3R may 
likewise exert a significant effect on the phenotype even in the heterozygous state, in the 
‘obesogenic’ environment.  This notion was supported by the linkage of a locus encoding 
MC3R on human chromosome 20q13.2 to the regulation of BMI, subcutaneous fat mass 
and fasting insulin (Lembertas et al., 1997).  We report common and rare novel variants at 
the MC3R locus which result in partially reduced activity of the MC3R in response to 
MSH, and demonstrate that the common variants, and possibly the rare variants, are 
associated with increased body fat and leptin levels (with additive effect), and perhaps 
decreased hunger, in human subjects, congruous with the phenotype of the Mc3r-/- mice.  
Of note is the presence of childhood or early onset obesity in all the carriers of the rare 
mutations (figure 5-3), although the significance of this is uncertain. 
 
There were varying reports of increased insulin-glucose ratio, HOMA, leptin, BMI, 
and body fat in humans with 6K/81I (Feng et al., 2005; Schalin-Jantti et al., 2003; 
Yiannakouris et al., 2004). Our finding of decreased insulin resistance despite increased 
body fat in subjects with 6K/81I appeared counterintuitive.  However, our finding is 
supported by a recently reported murine study comparing mc4r-/- and mc3r-/- mice which 
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developed severe obesity when fed with high fat chow, and showed that the MC4R 
knockout mice developed low adiponectin and increased insulin resistance as expected, but 
the MC3R knock mice maintained relatively normal adiponectin levels with mild insulin 
resistance only (Trevaskis et al., 2007).  This interesting murine phenotype lend support to 
our finding and suggests that this improved insulin resistance may be mediated by 
adiponectin, and this is an obvious area of further research for our cohort.  Our report 
reinforced the evidence that these two variants contribute significantly to the human 
phenotype by demonstrating a significant additive effect of 6K/81I on adiposity and leptin.  
Feng et al reported that the MC3R with 6K/81I resulted in reduced receptor activity, 
binding affinity, and protein expression compared to wildtype MC3R (Feng et al., 2005).  
Tao et al however reported there was no difference in receptor activity and ligand binding 
affinity for these two variants (Tao and Segaloff, 2004).  Our report has furthered this 
debate; we found that MC3R with 6K/81I had reduced receptor activity in response to 
MSH as reported by Feng, but we did not detect any difference in ligand binding, and there 
was qualitative evidence that the variant MC3R was well expressed on the cell surface.     
 
 The three rare variants were not found in other similar studies (Feng et al., 2005; 
Hani et al., 2001; Li et al., 2000; Schalin-Jantti et al., 2003; Yiannakouris et al., 2004).  
Isoleucine residue 183 of MC3R is located in the second intracytoplasmic loop of this G-
protein coupled receptor (Gantz et al., 1993a). Isoleucine at codon 183 is a highly 
conserved residue, present in the MC3R sequence of many other species, from teleost fish 
through to mammals (accession numbers: Zebrafish NP_851303, Chicken BAA32555, 
Mouse AAI03670, Rat NP_001020441, Human NP063941).  This hydrophobic 
  139
isoleucine was substituted by hydrophilic asparagine in Ile183Asn MC3R.  The 
transmembrane domain directly interacts with G proteins and controls cAMP production; 
this mutation may cause partial reduction in receptor function resulting from abnormal G 
protein interaction.  After our first communication of this mutation (Lee et al., 2002), Tao 
et al (Tao and Segaloff, 2004) and Rached et al (Rached et al., 2004) subsequently 
reported that the Ile183Asn MC3R had total abolished cAMP response to MSH, and 
Rached also reported a dominant negative effect on wildtype MC3R, and complete 
intracellular retention with no cell surface expression.  Our studies demonstrated near 
total but not complete loss of cAMP generation in response to MSH stimulation (figure 5-
2C), with normal cell surface expression, normal ligand binding affinity, and absence of 
dominant negative activity on wildtype MC3R. 
 
The Ala70Thr mutation affects the extracellular domain (Gantz et al., 1993a) 
within the critical region for binding activity (Schioth et al., 1997), where the 
hydrophobic alanine residue was changed to hydrophilic threonine.  The hydrophobic 
alanine residue at codon 70 is replaced by another hydrophobic residue Glycine in the 
MC3R of chicken, mouse, rat and spiny dogfish (accession number: AAS66720); thus it 
may be possible that the substitution by a hydrophilic residue (threonine) may result in a 
significant change in conformation and function of the receptor.  The met134Ile mutation 
is located at the second transmembrane region of the seventh transmembrane domain.  
The hydrophobic methionine is conserved in chicken, mouse, and rat.   
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The three novel rare mutations were not found in the population sample, nor 
reported elsewhere, and the clinical characteristics of our subjects coupled with the in-
vitro studies support their pathogenic role.  We believe that our report has shed light on 
the human MC3R mutation phenotype, and further studies with bigger numbers will 
continue to unravel the phenotype and support the role of MC3R in human weight 
regulation and pathogenesis of obesity.                       
The data in this chapter is published in Lee, Y.S., Poh, L.K., Kek, B.L., and Loke, K.Y. 




Unraveling the biology of human weight regulation through human obesity genetic 
studies: the quest to complete the unfinished jigsaw puzzle 
 
Human and animal genetics studies performed in the quest to elucidate the genes governing 
obesity have improved our understanding of weight regulation.  Whether this knowledge 
can be effectively applied to clinical practice remains to be seen. What is clear from these 
genetic studies is that they have challenged our traditional views of the pathogenesis of 
obesity, and changed our view of obesity as just a psychological disorder arising from sheer 
gluttony and poor discipline. The multitude of evidence now supports a physiological basis 
for weight dysregulation, where individuals may be predisposed to varying degree of 
obesity due to their genetic makeup, especially when exposed to the “right” environmental 
conditions. Some individuals may be simply predisposed to obesity at multiple genetic 
levels, and this may also make it very difficult for them to lose weight.  Current research 
reinforces the view that obesity is caused by both genetic and environment determinants.  
 
 There are various classifications of human obesity, the commonest of which is the 
classification into early onset or childhood obesity, and late or adult onset obesity. While 
the environment, behaviour and genetic make up contributes the obese phenotype, their 
role and contribution may vary between these two groups. Our hypothesis is that genetic 
factors have dominant pathogenic role in early onset obesity, while late onset obesity may 
be predominantly due to environmental factors.  Our studies and others have thus far 
supported the view that genetic variants and mutations are the predominant contributory 
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factor in childhood obesity.  Early onset obesity can be further subclassified into either due 
to single gene defects (monogenic form of obesity) such as MC4R mutations, or 
combination of several predisposing genetic variants, such as the POMC mutation 
Tyr221Cys and MC3R variant 6Lys/81Ile.  
 
 Although much attention has been focused on leptin-melanocortin system, there are 
a large number of other unidentified hormones, receptors, enzymes that are involved in the 
complex regulating mechanism governing energy homeostasis, waiting to be discovered. 
While the weight regulation mechanism is similar between rodents and man, differences 
may exist, and thus mere experimentation with knockout obese mouse models may not be 
adequate. The search for human genetic mutations in candidate genes predicted to affect 
weight regulation serves a very important purpose. By showing that loss-of-function 
mutations in these candidate genes, which occur naturally in humans, result in or 
predispose to human obesity, these “experiments of nature” validate the products of these 
genes as critical mediators of the weight regulation mechanism in humans. The discovery 
of these novel gene products will also collectively help to complete this unfinished jigsaw 
puzzle. These critical mediators in turn will become the focuses of intense, million dollar 
research efforts by pharmaceutical companies to produce new drugs to combat the 
worldwide epidemic of obesity. Indeed, elucidation of the complete human weight 
regulation mechanism and the pathogenesis of obesity will facilitate the design of novel 
therapeutic agents as adjuncts in the treatment of obesity. Obesity gene research contributes 
to our understanding of the molecular circuitry controlling appetite and energy balance. By 
identifying these genes and their products, and understanding how they confer 
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susceptibility and interact with other factors to lead to obesity, we can then devise more 
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